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 i 
ABSTRACT 
Abstract Title:    Dose inter-comparisons between computer planning,        
in-vivo and phantom measurements for Iridium-192 HDR 
Brachytherapy 
Introduction 
During gynaecological high-dose rate (HDR) intracavitary brachytherapy (ICBT), in-
vivo dosimetry is done to monitor the dose received by the bladder and rectum. This 
study was aimed at validating the need to do in-vivo dosimetry during ICBT. Thirty 
patients were recruited to participate in the study. Treatment setup data from the 
thirty patients was used to reproduce applicator and in-vivo diode treatment setups in 
a water phantom. Radiation doses administered to the patients were replicated in the 
water phantom to measure the doses at marked dose reference positions.  
 
Method 
Bladder identifying apparatus together with in-vivo bladder and rectal diode probes 
were inserted into the separate organs to measure the dose with the patient in the 
treatment setup position. Orthogonal x-ray images of the patient were taken and 
developed. International Commission for Radiological Units (ICRU 38) and American 
Brachytherapy Society (ABS) dose reference points recommendations were used to 
mark the bladder and rectal dose reference points onto the x-rays. On the same x-ray 
images, bladder and rectal diode dose points were also marked and then scanned 
into a treatment planning system (TPS). Patients were treated using optimized 
treatment plans and the dose registered by in-vivo dosimeters was recorded. For 
each treatment procedure, the applicator treatment setup was replicated in a water 
phantom and bladder and rectal diode dose measurements were done and recorded. 
Comparisons were made between the TPS planned doses, in-vivo and in-vitro doses 
for each treatment and patient.  
 
Results 
Thirty patients participated in the study. The ring and tandem applicator was used on 
19 patients from whom valid data was drawn from 39 insertions. The vaginal cylinder 
and tandem combination (combo) was used on 11 patients from whom useful data 
was extracted from 11 insertions. The ratio of ICRU to in-vivo doses using the ring 











respectively and correspondingly, 1.2 ± 0.5 and 1.8 ± 0.7 for the bladder and rectum 
when using the  vaginal combo applicator. All in-vitro measurements closely 
confirmed the doses computed by the TPS and measured by the in-vivo diodes. For 
the rectum, in-vivo doses were higher than the TPS computed doses i.e. average 
ratio of TPS to in-vivo doses were 0.7 ± 0.1 and 0.8 ± 0.2 for the ring and tandem and 
vaginal combo applicators. The TPS planned doses closely compared to in-vivo 
doses for the bladder 1.1 ± 0.3 and 1.0 ± 0.1 for the ring and tandem and vaginal 
combo applicators. The variation in dose received by the bladder on separate ICBT 
insertions (intra-patient dose variation) calculated from TPS and in-vivo dose data 
was correspondingly 1.3 Gy and 0.6 Gy while for the rectum was 0.2 Gy and 0.5 Gy 
respectively. The random error associated with reproducing patient setups in the 
water phantom ranged from 0.1 Gy to 0.4 Gy for both bladder and rectum dose 
measurements. Paired sample T-test showed that TPS and in-vivo dosimetry had 
similar sample means and good correlation, i.e. p = 0.00 and average correlation 
coefficient > 0.75. Regression analyses of TPS against in-vivo doses showed 
scattered data plots with no linear relationship between data and relatively low R-
squared values for plotted graphs, i.e. R2  0.60. 
 
Conclusion 
Treatment planning using orthogonal radiographs and ICRU dose reference points to 
monitor doses received by organs at risk (OARs) is a fairly good method of verifying 
doses during ICBT. Bladder in-vivo dose measurements agreed with TPS doses 
corresponding to the ‘setup point’ in the patient for both the ring and tandem and 
vaginal combo applicators. Rectum in-vivo dose measurements were remarkably 
higher (by up to an average of 31%) compared to TPS planned doses. This may 
mean that the TPS underestimates the dose that the rectum receives during ICBT. 
In-vitro measurements confirmed the relationship between TPS planned doses and 
in-vivo measurements in the bladder and rectum for both the ring and tandem and 
vaginal cylinder applicators. Regression analysis cannot be reliably used to predict 
in-vivo and TPS planned doses. Therefore, individualized treatment plans must be 
done for each patient for each treatment. Computerised treatment planning and in-
vivo dosimetry are separate complementary procedures that may be done 
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CHAPTER 1 INTRODUCTION 
1.1 Introduction 
Brachytherapy comes from the Greek word βραχυς brachys, which means a 
short-distance, and is a form of radiotherapy in which a radioactive source is 
inserted into or close to a tumour. Brachytherapy is mainly used in 
combination with external beam radiotherapy (EBRT), chemotherapy and 
surgery; however, it can also be used alone. (Gerbaulet, et al., 2005) & 
(Anon., 2012). In brachytherapy, the radioactive source is encased in a thin 
titanium wire capsule which allows radiation to be emitted into the surrounding 
tissue  and at the same time, protects against direct contact of the 
radioisotope with body tissue and interaction with bodily fluids. A desirable 
characteristic of brachytherapy sources is that they release short-range 
radiation that affects a localized region around the tumour volume. This limits 
unnecessary irradiation of normal healthy tissue and organs surrounding the 
tumour. Studies done to investigate the efficacy of brachytherapy have shown 
that treatment using brachytherapy is comparable to surgery and external 
beam therapy, or is enhanced when used adjuvant to surgery, and/or EBRT. 
(Viswanathan & Petereit, 2007) (Pickles, et al., 2009), (Haie-Meder, et al., 
2009), (Battermann, et al., 2004) & (Galalae, et al., 2004). 
1.1.1 History of Brachytherapy 
In 1896 radioactivity was discovered by Henri Becquerel after a photographic 
film was accidentally exposed to uranium. Brachytherapy started as early as 
1901, Pierre Curie postulated that it was possible to place a radioactive 
source inside a tumour. Danlos investigated this and found that the tumour 
shrunk as a result of the radiation. This gave birth to the practice of 
brachytherapy and in 1901 the first cancer treatments with radium were done. 
In 1901, Danlos and Bloc used radiation to treat lupus at the St. Louis Hospital 
in Paris, radium implants were done in the USA by Robert Abbe in 1905 at St 












started to treat patients using radium  (Gerbaulet, et al., 2005) & (Anon., 
2012).  
The use and development of brachytherapy decreased in the middle of the 
twentieth century because operators were exposed to radiation while 
manually handling radioactive sources during patient treatments. This 
challenge was overcome in the 1950s and 1960s with the use of new 
alternative radioactive sources, e.g. caesium and iodine, and the new design 
of equipment which provided shielding to the source and remote afterloading 
systems.   
The development of afterloading systems with the capability to change source 
positions and dwell times has greatly enhanced the quality of treatments. 
Advances in medical imaging  have also facilitated “more accurate definition 
of target volume and the localisation of adjacent normal tissue together with 
computerised dosimetry  and better knowledge of the radiobiology involved”, 
and have made brachytherapy much more accurate and safe (Gerbaulet, et 
al., 2005). 
1.1.2 Types of Brachytherapy 
There are four ways of describing brachytherapy and these depend on: 
i. Source placement, 
ii. Overall treatment duration,  
iii. The dose rate, and 
iv. Method of source loading. 
1.1.2.1 Source Placement 
 Interstitial brachytherapy is when radiation sources are placed inside 
the tissue or tumour, e.g. for treatment of the breast, skin and prostate. 
 Contact /plesiobrachytherapy is when the radiation sources are placed 
close to or next to the tissue or tumour. Within contact brachytherapy 
there are four different types of brachytherapy, namely intracavitary, 
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- Intracavitary brachytherapy is when radioactive sources are 
inserted into body cavities close to the tumour, e.g. in the cervix and 
nasopharynx . 
- Surface brachytherapy is when radioactive sources are placed 
directly over the tissue to be irradiated, e.g. on the skin and soft 
tissue sarcoma. 
- Intraluminal brachytherapy is when sources are inserted into a 
lumen, e.g. oesophagus and bronchus. 
- Endovascular brachytherapy is when radiation sources are inserted 
into small or large arteries or veins.  (Gerbaulet, et al., 2005) and 
(Podgorsak, 2005) 
1.1.2.2 Overall Treatment Time 
 Permanent implants are small radioactive sources that are 
encapsulated in very thin metal capsules, i.e. iodine seeds. The 
radioactive seeds usually have a short half-life and are implanted inside 
the tissue to irradiate the tumour over the lifetime of the source (Devlin, 
2007). The radiation strength of the seeds is very low such that there is 
no afterloading required to place the seeds into the tissue. 
 Temporary implants are placed inside the tumour site for a given 
amount of time until the prescribed dose is delivered after which they 
will be removed (Gerbaulet, et al., 2005). Caesium and iridium are the 
elements of choice for most temporary implants and they are placed 
into the tumour site in the patient using remote afterloading systems. 
1.1.2.3 Dose Rate 
 Low-dose rate brachytherapy systems will have radioactive sources 
which deliver dose rates of about 10 Gy per day, i.e. 0.4 – 2 Gy/hr. 
 Medium-dose rate brachytherapy systems have radioactive sources 
which deliver dose rates of about 10 Gy per hour, i.e. 2 – 12 Gy/hr. 
 High-dose rate brachytherapy systems have radioactive sources which 












 Pulsed-dose rate (PDR) brachytherapy is another form of 
brachytherapy that uses an afterloading system with an Iridium-192 
source. Ten minute-dose pulses are given are given each hour to 
achieve a dose equivalent of 60 cGy per hour. The optimization of the 
dose accomplished by this method is the same as that of HDR and the 
biological effect is the same as that obtained when using LDR (Devlin, 
2007). 
1.1.2.4 Method of Source Loading 
 Hot loading is when the radioactive sources are loaded into the 
applicators before the applicator is inserted into/onto the patient. 
 Afterloading is when the applicator is first placed into position and the 
radioactive sources will be loaded thereafter by hand or automatic 
remote afterloading (Gerbaulet, et al., 2005) and (Podgorsak, 2005). 
1.2 Afterloading Devices 
The  careful, accurate and precise placement of applicators, guides, catheters 
or tubes into or next to tissues, in which radioactive sources will be loaded is 
called afterloading. Positioning of radiation sources is of utmost importance in 
brachytherapy. There are two types of afterloading, namely manual and 
remote afterloading systems. 
1.2.1 Manual Afterloading 
Manual afterloading is when the applicators, gutters, tubes, catheters, needles 
and the sources themselves are placed and loaded by hand.  
1.2.2 Remote Afterloading 
Remote afterloading systems move radiation sources from the source safe 
into applicators placed in or onto the patient. Current remote afterloader 
systems are capable of accurate and precise positioning of the source and 
retract the source back into the radiation safe after each treatment. The 
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released into the channel prior to treatment, encounters an uneven pathway, 
i.e. kinks along the source channel, or if a treatment room door with interlocks 
is opened, or when an emergency switch is activated. This method of 
administering radiation achieves good radiation protection, and with the help 
of good imaging modalities enables more accurate positioning of source 
applicators. Remote afterloading systems also allow users to change the 
source position and dwell times to achieve different dose distributions, thereby 
achieving individualised patient treatment (Gerbaulet, et al., 2005), (Devlin, 
2007)  & (Podgorsak, 2005). 
1.3 Radiobiology Concepts of Brachytherapy 
Dose distribution, treated volume, dose rate and treatment duration greatly 
determine the biological results of radiotherapy. The degree to which each of 
these aspects influence the outcome of radiotherapy is different for 
brachytherapy and external beam therapy. High doses are given in short 
times for a small number of fractions in brachytherapy. This is not applicable 
in external beam therapy since normal tissue cannot withstand such high 
doses due to the volume-effect relationship: small volumes of normal tissue 
(e.g. 1 – 2 cm3) are capable of withstanding high doses of radiation that larger 
volumes would not withstand. This phenomenon may be explained as 
resulting from the nature of vascular supply which is arranged in three 
dimensions inside normal tissues (Gerbaulet, et al., 2005) and (Devlin, 2007). 
Similar radiobiology characteristics shown in continuous LDR, 
hypofractionated HDR and hyperfractionated PDR are also evident in normal 
fractionated external beam therapy. However, the major advantage of 
brachytherapy is the steep dose gradient as a function of distance from the 
source. Furthermore, radiobiologic dose sparing is also achieved due to the 
decrease of the dose and dose rate with distance (Gerbaulet, et al., 2005) and 
(Devlin, 2007). 
Tumour repopulation, repair of sub-lethal damage, and the extent to which 
tumour re-oxygenation occurs, greatly influence the outcome of the treatment. 












per fraction in external beam therapy. Dose rate plays an important part in 
influencing radiobiological systems. Outcomes of radiotherapy reduce as the 
dose rate reduces since there will be more repair of tumour cells (Devlin, 
2007). 
1.4 Properties of Brachytherapy Photon Sources 
1.4.1 Practical Characteristics of Photon Sources 
Radioactive sources used in brachytherapy are always enclosed in a thin 
metal capsule for purposes of: 
 controlling the emission of radiation; 
  giving source rigidity; 
 containing other undesired types of radiation, i.e. α or β 
particles that may be released during source decay. 
The metal capsule also serves to avoid direct contact of the radioactive 
source with tissue and also prevents the interaction of the radiation source 
with bodily fluids (Podgorsak, 2005). The desired radiation from a 
brachytherapy source is made up of the following: 
 γ- rays, which constitute the fundamental part of the radiation 
produced; 
 characteristic x-rays which are produced occasionally as a result 
of electron capture and intrinsic transformations that take place 
in the source; 
 characteristic x-rays and bremsstrahlung that are produced in 
the capsule enclosing the source. 
The selection of a radioisotope that releases a particular radiation of 
preference in brachytherapy is determined by a number of physical and 
dosimetry properties (Podgorsak, 2005), which are: 
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iii. Half-value layer in lead and other shielding materials; 
iv. Specific activity; 
v. Source strength; 
vi. Inverse square decrease in dose as a function of distance from the 
source. 
Table 1.0 (see next page) gives a list of the properties of radioisotopes most 
used in brachytherapy. 
1.5 Gynaecological High-Dose Rate Brachytherapy 
This research is concerned with gynaecological high-dose rate (HDR) 
brachytherapy, which is a form of intracavitary brachytherapy. Cancers of the 
uterine cervix, uterine body and vagina are usually treated using intracavitary 
brachytherapy. A variety of applicators can be used for insertions in 
gynaecological brachytherapy. A chosen applicator for a particular patient is 
placed into the body cavity and images of the patient are taken with the 
applicators in place in order to determine the position of the applicators 
relative to the tumour. Modern image guided radiotherapy (IGRT) remote 
afterloaders allow guided placement f applicators to the region of interest 
close to the tumour. After correct placement and positioning of the applicators, 
radioactive sources will move into specified positions (dwell positions) for 
predetermined dwell times to achieve a dose distribution to adequately cover 
the tumour during treatment. Caesium-137, Iridium-192 and recently Cobalt-
60 are commonly used for treatment of gynaecological cancers.  
1.5.1 Side Effects 
External beam radiotherapy followed by intracavitary HDR brachytherapy has 
become the standard treatment for gynaecological malignancies (Gerbaulet, 
et al., 2005). However, patients who have undergone the treatment regime 
may suffer from bladder and rectum early and late complications as side 
effects of the treatment due to the closeness of these organs to the sources of 
radiation during intracavitary brachytherapy (Gerbaulet, et al., 2005), (Wang, 












is an insignificant difference in the occurrence of complications in patients who 
receive either LDR or HDR brachytherapy  (Viani, et al., 2009). 
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Table 1.1 Possible complications after LDR or HDR brachytherapy 
(Devlin, 2007)  
Acute Late 
Urine perforation Proctitis 
Vaginal laceration Ulceration of the bladder or rectum 
Fever Fistula 
Thrombotic events Stricture 
Anaesthesia related nausea Vaginal stenosis 
 
Table 1.1 above shows the complications that can arise from either LDR or 
HDR brachytherapy. 
 
HDR brachytherapy is used at most centres, since it facilitates treatment for 
many patients on any single day to achieve the same results as LDR 
brachytherapy (Viani, et al., 2009). There are two categories of factors that 
contribute to radiotherapy-induced toxicity: radio-brachytherapy techniques 
and doses, and/or non-irradiation techniques, e.g. surgery, concomitant 
chemotherapy and diabetes (Gerbaulet, et al., 2005). This research is 
interested in complications that may be attributed to radiation and will look at 
methods of dosimetry used to measure and monitor the doses that the organs 
at risk (OARs) receive during intracavitary HDR brachytherapy.  
1.6 Dissertation Aims 
The aim of this thesis is to introduce and evaluate a reliable method to 
perform in-vivo dosimetry on patients undergoing intracavitary HDR 
brachytherapy as part of treatment for gynaecological malignancies at Groote 
Schuur Hospital, Cape Town. The doses to patients’ critical organs, i.e. the 
bladder and rectum are going to be computed using a treatment planning 
system (TPS), which will derive information from orthogonal films. In-vivo dose 
measurements in the bladder and rectum will be made in patients on a 
separate treatment day. A water phantom with accessories to mount patient 












of patients and dose measurements will be made in water. Comparisons will 
be made between the values of dose computed from the TPS, in-vivo dose 
measurements in patients and measurements made in water for the dose 
received by the bladder and rectum during gynaecological intracavitary 
brachytherapy. Mathematical analysis of the computed and measured values 
will be made to investigate the relationship between these values. The 
investigator will compare computed with measured values to ascertain 
whether the treatment planning system gives a true reflection of the actual 
dose received by the OARs during treatment. Evaluation of doses measured 
in patients and doses measured in a water phantom will be compared to 
establish if the inhomogeneities present in patient anatomies should be taken 



























CHAPTER 2 LITERATURE  REVIEW 
2.1 Sources of Radiation 
Radiation used for medical purposes is sourced either from radioactive 
materials or from x-rays produced through the bremsstrahlung process. 
Radioactive substances are the main source of radiation used for 
brachytherapy procedures, although there is advanced on-going research of 
employing bremsstrahlung techniques to produce low energy x-rays to be 
used in brachytherapy. This research will cover radiation derived from 
radioactive isotopes since the research was done using Iridium-192.  
2.1.1 Radioactivity 
Radioactivity was discovered by Antonio Henri Becquerel in 1896 and is 
defined in general terms as the random and spontaneous decay of unstable 
nuclei in elements, producing radiation in the process. The radiation produced 
may be in nature of particles, electromagnetic radiation or a combination of 
both (Khan, 2010). Rutherford and Soddy in 1902 and later Bateman in 1910, 
came up with laws that characterize the exponential disintegration of 
radioactive substances with time (Podgorsak, 2005).    
A typical radioactive decay involves an arbitrary parent nucleus P that decays 
with a decay constant into a stable daughter nucleus D (Podgorsak, 2005): 
 
                                                      P            D                                        . . . (2.1) 
At any time t, there will be Np(t) number of parent nuclei which will be 
decaying according to the mathematical relationship: 
                                                 Np(t) = Np(0)e- λpt                                   . . . (2.2) 
Np(0) being the original number of nuclei at the beginning of the decay, i.e. 












1962 by the International Commission on Radiological Units (ICRU, 1962). 
The latest definition of activity (ICRU, 1980) is:   
“ The activity A of an amount of radioactive nuclide in a particular energy state 
at a given time is the quotient of    by dt where    is the expected value of 
the number of spontaneous nuclear transitions from that energy state in the 
time interval dt.”  
i.e.                                                       ⁄                                         . . . (2.3) 
Therefore, the parent nuclei activity Ap(t) at time t is:  
                                                       ( )     ( )                               . . . (2.4) 
Where the activity at the beginning of the disintegration when t = 0 is   ( ) . 
Another important radioactive measurement unit is the half-life    ⁄ , which is 
defined as the time taken for either the number of nuclei or the activity to 
decay to half the initial value (Khan, 2010): 
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 ⁄                                     . . . (2.5) 
i.e.                              
 ⁄
 
   
  
                                                               . . . (2.6) 
2.1.2 Photon Beams 
A beam of radiation, either x-rays emanating from a target or γ-rays from a 
radioactive source, consists of many photons, possibly of different energies 
(Khan, 2010). The photon fluence (Φ) represents the number of photons    
that are incident on a hypothetical sphere having a crossing-sectional area   ,  
i.e.: 
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2.2 Interactions of Ionizing Radiation  
Photons are known as indirectly ionizing radiation, since charged particles, i.e. 
directly ionizing particles are produced when photons pass through a medium. 
A beam of photons, i.e. x- or γ-rays, traversing through matter often transfers 
energy to the medium. Usually, electrons are emitted from the absorbing 
medium as a result of the energy transfer. These secondary electrons release 
their energy by effecting further ionization and excitation of atoms with which 
they collide as they traverse through the medium. (Khan, 2010). When 
radiation is incident on body tissues it may produce ionization and excitation 
of atoms within the tissue, resulting in enough energy being deposited within 
the cells and thus incapacitating their ability to reproduce. When photons 
interact with matter there are three main processes that produce secondary 
high-speed electrons in the absorbing medium (Khan, 2010):  
i. Photoelectric effect; 
ii. Compton effect; and 
iii. Pair production 
2.2.1 Photoelectric Effect 
Photons with low energies interact with matter predominantly by the 
photoelectric effect. The photoelectric effect involves interaction between a 
low energy photon and an atom and does not occur between a photon and a 
free electron. All the energy from the incident photon is absorbed in the atom 
and an electron is ejected in the process. The ejected electron takes up the 
energy of the photon   minus the binding energy        of the electron, giving 
the electron kinetic energy    (Baltas, et al., 2007).  
 
                                                                                                       . . . (2.8)     
 
The probability of photoelectric effect occurring is highest for K-shell electrons, 
i.e. approximately 80 % of the interactions involve  -shell electrons. The 
probability for photoelectric effect occurring for  - and -shell electrons drops 












on the atomic number of the absorbing medium that can be approximated by 
the mathematical equation: 
                                       ⁄                                                              . . . (2.9)  
The dependence of photoelectric effect on the atomic number of the 
absorbing material is exploited in diagnostic radiology where the different   of 
tissues, e.g. bone, muscle, fat and adipose tissue magnifies the differences in 
x-ray absorption, which results in a well defined topographic anatomical image 
(Khan, 2010).  
2.2.2 Compton Effect  
Compton scattering (incoherent scattering) occurs when a photon collides with 
a free electron and there is an inelastic collision. The photon imparts some of 
its energy to an atomic electron which scatters away from the atom, while the 
photon is deflected with less energy at an angle to its direction of incidence 
(see Fig 2.1). If the electron is assumed to be at rest and a free electron, then 
the energy of the scattered photon in relation to the scattering angle   is given 
by (Baltas, et al., 2007) 
                                             
 
  ( 
     
⁄ )(      )
                              . . . (2.10) 
where the energy of the photon at incidence is  , the rest energy of the 
electron is      , and    is the kinetic energy imparted to the recoil Compton 
electron: 
                                                
( 
     
⁄ )(      )
  ( 
     
⁄ )(      )
                   . . . (2.11) 
The energies of the recoil electron    and the scattered photon      are 
determined by the scattering angle and the incident photon energy as shown 
in equations 2.10 and 2.11 above. Compton interaction relies on the number 
of free electrons per unit mass of absorbing material and does not depend on 
the atomic number   of the material. The Compton effect also depends on the 
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comparatively larger than the binding energy of the electron for Compton 
scatter to take place. 
 
Figure 2.1 Angular distribution of photons with incident energies of up 
to   = 1 MeV scattered by a free electron (Baltas, et al., 2007) 
2.2.3 Pair Production 
Pair production can occur when photons with energies greater than 1.022 
MeV traverse through matter. During pair production, the photon is involved in 
intense electromagnetic interactions with an atomic nucleus such that all of 
the photon’s energy is absorbed and an electron and positron pair is created 
(Khan, 2010). A photon with an energy equivalent to 1.022 MeV has sufficient 
energy to produce the electron and positron pair since the rest mass energy of 
the electron is 0.511 MeV and the incident photon energy is enough to 
produce a positron and an electron pair (see Fig 2.2 below). The positron 
which was produced during pair production loses its energy as it moves in the 
absorbing medium by ionization, excitation and bremsstrahlung. Somewhere 
along the way, the positron will interact with a free electron and create two 
annihilation photons with energies of 0.511 MeV each. The two photons 
produced  are emitted in opposite directions as a result of conservation of 












through matter, the probability of pair production occurrence is proportional to 
the square of the atomic number of the absorbing medium. 
 
Figure 2.2 Formation of electron pair in pair production (Wikidot, 2012) 
In brachytherapy the most common interactions are as a result of either the 
photoelectric or Compton effects. This is as a result of the ‘intention’ of 
brachytherapy and therefore the energies of the gamma sources of radiation 
selected for use in brachytherapy. 
 
Photons react with matter either by photoelectric, Compton or pair production 
processes, while charged particles, i.e. protons, electrons, α-particles and 
nuclei, produce ionization and excitation when they traverse through a 
medium (Khan, 2010). The particles experience radiative loss of energy 
(bremsstrahlung) following collisions between the particle and the nucleus. 
Scattering of particles also happens and this is accompanied by a minimal 
loss of energy. During ionization, the rate at which the particle loses energy is 
proportional to the square of the particle’s charge and inversely proportional to 
the square of its speed. This means that the ionization or dose released into 
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2.3 Exposure 
Since the inception of the use of radiation in medicine, radiation workers have 
always been conscious of the necessity to measure patient response to 
radiation in terms of the quantity of radiation and duration for which the 
radiation was administered (Godden, 1988, p. 3). Holzknecht was the first to 
try to estimate dose measurements in 1902. He observed that a fused mixture 
of potassium chloride and sodium carbonate changed colour as a function of 
time of radiation exposure. Numerous efforts have been made since then to 
try to measure patient dose by means of radioactive substance used, activity, 
ionization produced in air (exposure), energy absorbed by tissue (absorbed 
dose), a combination of two or all of these methods (Godden, 1988). The 
various methods used to measure radiation caused a lot of misunderstanding 
until in 1956, the ICRU came up with a definition of the roentgen in terms of 
the exposure dose based upon the capability to ionize. The definition of 
exposure    is defined (ICRU, 1980) as: 
“The exposure   is the quotient of    by   where the volume of dQ is the 
absolute value of the total charge of the ions of one sign produced in air when 
all electrons (negatives and positives) liberated by photons in air of mass    
are completely stopped in the air.” 
i.e.                                                       ⁄  C·kg-1                          . . . (2.12) 
 where the unit of exposure is the roentgen (R), which is: 
                                                      1 R = 2.58 X 10-4 C·kg-1          
2.4 Absorbed Dose                                                           
In 1904 Beclere discovered the importance of measuring radiation absorbed 
in tissues in radiology and in 1950 the ICRU acknowledged the need to look 
into how ionising radiation is related to biological effects produced by the 












deposited per unit mass (ergs) was formulated and absorbed dose was 
defined (ICRU, 1954): 
 
Absorbed dose is the energy imparted per unit mass to matter by ionizing 
radiation at a specified point.  
 
The unit of absorbed dose is the     where: 
                      
Absorbed dose is also defined (ICRU, 1980) as the quotient of    by    
where    is the mean energy released by ionising radiation into the medium 
of mass dm, i.e.  
          
The special name for the unit of absorbed dose is the gray (  )  where 
                , 
or, from first principles 
              . 
 
Absorbed dose in brachytherapy is obtained from a combination of the 
exposure due to a given activity of a radionuclide and a factor relating 
exposure to the actual absorbed dose (Godden, 1988). A factor Wair/e relates 
the energy released by an exposure of radiation to the absorbed dose in air, 
where Wair is the energy necessary to create an ion pair in air (Godden, 
1988). Therefore, an exposure   of radiation creates an absorbed dose in air 
Dair, i.e. 
                                                        (      )                                 . . . (2.13) 
For any medium, energy absorbed per unit mass is proportional to the mass 
energy absorption coefficient (µen/ ). Therefore, the relationship between the 
absorbed dose in the medium, Dmed and absorbed dose in air Dair, is given by: 
                                                          ρ⁄     
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The term      ⁄         gives the ratio of mass energy absorption coefficient for 
the medium to the absorption coefficient of air. Replacing      by the term in 
equation (2.13) above, equation (2.14) becomes 
                                                    (      )    ρ⁄     
                   . . . (2.15) 
From Wair/e = 33.85 J·C-1 (ICRU, 1979), the exposure can expressed in terms 
of the SI units of C·kg-1 
                                               (         ρ⁄     
   )  J kg             . . . (2.16) 
and,                                
                                               (         ρ⁄     
   )  cGy               . . . (2.17) 
when exposure is expressed in terms of roentgens ( ). 
 
The absorbed dose in tissue is now obtained from the kinetic energy released 
per unit mass (kerma). This theory was initiated (ICRU, 1962) to bring to light 
that transfer of energy to matter from indirectly ionizing radiation happens in 
two stages (Godden, 1988). The first stage involves transfer of energy from 
indirectly ionizing particles, i.e. photons and neutrons, by different interactions 
(photoelectric effect, Compton effect, pair production, etc.) to secondary 
charged particles (electrons). Secondary charged particles transmit their 
energy to the medium via ionization and excitation (Podgorsak, 2005).  
 
Kerma  is the mean energy transmitted from indirectly ionizing radiation to 
charged particles in the medium        per unit mass by   , where     is the 
sum of initial kinetic energies of all charged ionizing particles:  
              
Under conditions of electronic equilibrium, secondary charged particles 
experience a gradual decrease in speed as they traverse through matter, 
resulting in the loss of most of their energy to the medium (Godden, 1988).  
 
The energy transferred to the medium, i.e. absorbed dose     , is related to 












                                                    D = K (1 – g)                                 . . . (2.18) 
where g represents the fraction of secondary charged particle energy lost in 
producing bremsstrahlung. Therefore, for a particular air kerma Kair, the 
absorbed dose in air Dair is specified as: 
                                                                 (  –   )                       . . . (2.19) 
From equations (2.14) and (2.19) the dose imparted to a medium is expressed 
in terms of kerma as: 
                                                         (   )    ρ⁄     
    
Also, 
                                                 
  
ρ⁄   ( 
  
ρ⁄ )(    ) 
where the mass energy transfer coefficient is     ⁄ , this means  
          (   ρ⁄ )(   ρ⁄ ) 
In brachytherapy g is less than 0.5%, meaning 
                                               ( 
  
ρ⁄ )
   
  ( 
  
ρ⁄ )
   
 
Therefore, 
                                                              ρ⁄     
                          . . . (2.20) 
For photons with energies between 200 keV and 2 MeV, [ 
  
ρ⁄   is equivalent 
to the numerical value 1.11 in water (Godden, 1988). Therefore, the absorbed 
dose of most radionuclides used in brachytherapy (except Iodine-125) is given 
by: 
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2.5 Biological Effects of Radiation 
 
Secondary electrons produced from interactions of photons with matter 
release energy as they are slowed down when traversing through the 
medium. This energy is absorbed  in the surrounding tissue and the outcome 
produced by absorption of ionizing radiation in a population of cells can be 
classified into three ways, namely: 
1. Ionisation may occur outside the critical region resulting in no damage 
to the cells; 
2. Ionisation may occur within the critical region such that enough energy 
to damage the cell may be deposited within. The cell loses its ability to 
reproduce and this is known as lethal damage; 
3. Partial ionisation may take place within the cell’s critical region inflicting 
damage without necessarily killing the cell, i.e. sub-lethal damage. 
The cell may retain enough capability to repair itself and experience 
total recuperation from the effects of radiation. 
The extent to which cell damage occurs is dependent on the amount of dose 
administered (Godden, 1988). In brachytherapy, dose is administered in a 
number of fractions sufficient to destroy the malignant cells, while at the same 
time allowing sufficient time between each fraction to facilitate normal tissue 
cell repair. Continuous low-dose-dose rate irradiation may be regarded as 
equivalent to a vast number of small fractions. From this knowledge, this 
means that repair of sub-lethal damage increases with reduction in dose rate 
up to a point where all the sub-lethal damage is repaired and at this point the 
dose rate effect no longer applies, i.e. the death rate per cell cycle is the same 
as the birth rate (Godden, 1988). Dose rates currently used for brachytherapy 
treatments are sufficient to hamper cell division while killing more tumour cells 
than normal tissue for the same dose. 
Low-dose rate (LDR) brachytherapy has been widely accepted to produce 













i. As a result of the sharp dose gradient around sources, the tumour is 
subjected to a higher dose rate and subsequently more radiation, 
with less dose being delivered to the surrounding normal tissue.  
ii. The range of dose rates enables the repair of sub-lethal damage to 
occur during the treatment. 
iii. The low oxygen enhancement ratio (OER) gives advantages to 
brachytherapy. 
 
2.6 High-Dose Rate versus Low-Dose Rate 
At many centres, treatment of patients is done using HDR brachytherapy 
sources as opposed to using LDR brachytherapy. Numerous research has 
been done to compare clinical outcomes of HDR and LDR brachytherapy 
(Tamaka, et al., 2012), (Wang, et al., 2010), (Stewart & Viswanathan, 2006), 
(Hareyama, et al., 2002), (Kim, et al., 2001). However, there seems to be no 
binding universal agreement on this issue based on clinical data outcomes, 
i.e. overall survival rates and early and late tissue complication rates. Most 
centres use HDR because of a number of reasons that include the capacity to 
treat more patients, convenience of treatment on an outpatient basis, minimal 
exposure to staff etc (see Table 2.1). 
2.7 Iridium-192 
Iridium-192 was first used in brachytherapy by Ulrich Henschkle in 1958. 
Initially it was in the form of seeds, but these were replaced by iridium wires 
which were started to be manufactured in the early 1960s and these were 
used in the Paris System developed at the Institut Gustave Roussy (Godden, 
1988). Iridium-192 has virtually replaced Radium-226 as the radionuclide of 
choice for many brachytherapy applications. It has a high specific activity, 
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Iridium-192 decays 95% through β- particles to the 3rd and 4th excited states of 
Platinum-192. 192Pt further de-excites to the stable state of 192Pt by emission 
of several γ-rays (Baltas, et al., 2007). 
                                                                            +                    . . . (2.22) 
The β-rays emitted have energies of 530 keV and 670 keV, while γ-rays 
released in achieving stable status are of 370 keV average energy (Godden, 
1988). 
2.8 Intracavitary Brachytherapy 
Intracavitary brachytherapy is when radioactive sources are placed inside 
natural body cavities to administer a radiation dose for therapeutic purposes. 
Since the inception of brachytherapy at the beginning of the 20th century, 
brachytherapy techniques have been used to treat many lesions, e.g. cancers 
of the bladder, anus, rectum, antrum, oesophagus, nasopharynx and auditory 
tube. However, the most common use of brachytherapy has been in the 
treatment of gynaecological malignancies (Godden, 1988). Gynaecological 
brachytherapy enables placement of radiation sources in close proximity to 
the tumour, allowing a high radiation dose to be delivered to the neoplasm 
while sparing normal surrounding tissue as a result of the steep dose gradient 
of brachytherapy radiation. This characteristic also means that for large 
tumours, brachytherapy alone is not sufficient to achieve curative intent. It has 
almost become standard practice for the treatment of gynaecological 
malignancies to combine intracavitary brachytherapy (ICBT) with external 
beam radiotherapy (EBRT). Numerous research has been done which 
established that tumour control rates achieved using EBRT and ICBT are 
considerably enhanced than with EBRT alone (Viswanathan & Petereit, 2007). 
ICBT may be administered before, during the course of, or after EBRT 
(Godden, 1988). The clinical outcome of brachytherapy partially depends on 













Table 2.1 Comparison between high-dose rate and low-dose-rate 
brachytherapy (Stewart & Viswanathan, 2006) 
 Advantages Disadvantages 
Low-dose rate 
 Approximately 100 years of data 
available, 
 Doses are standardised, 
 Treatment plans are 
standardised, 
 Treatment plans are 
standardised, 
 Two insertions at maximum 
 Inpatient treatment, 
 Staff are exposed to radiation, 
 Source strength a limiting factor, 
 Availability of sources is limited, 
 General or spinal anaesthesia 
required, 
 Patient has long bed rest, 
. anticoagulation required, 
. constipating medication needed, 
. pain control required for the 
patient. 
High-dose rate 
 Outpatient treatment, 
 Time of administration is short, 
 Source strength is standard,
 Sources are easily available, 
 Conscious sedation using IV is 
possible, 
 Reassessment of tumour size 
possible with multiple fractions, 
 Normal tissue dose optimization 
possible, 
 Minimal exposure to staff, 
 Board stabilizes applicator 
during treatment  
 High risk of errors: 
. Intensive quality assurance 
required, 
. Intensive maintenance needed, 
. Intensive physician/physicist time 
required, 
 Number of treatment fractions is 
more than two, 
 Treatment to be done on insertion 
day, 
 Capital costs are high, 
 Caution to be exercised when 
treating large tumours, 
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It is crucial that applicators are placed accurately and precisely in order to 
maintain the reproducibility of the treatment setup and achieve local tumour 
control and reduction in morbidity. Technical adequacy of the implant or 
applicator also plays a pivotal role in establishing local tumour control 
(Viswanathan & Petereit, 2007). The basic equipment and facilities required to 
administer HDR ICBT are an adequately radiation shielded procedural room 
where applicator insertion and the treatment procedure are carried out, an 
HDR remote afterloader, imaging equipment for planning, i.e. anterior –
posterior (AP) and lateral (LAT) x-ray images, computed tomography (CT),or 
magnetic resonance imaging (MRI), as well as treatment planning software. In 
this research images were acquired using conventional x-ray equipment and 
treatment planning was done using AP and LAT x-ray radiographs only.  
Patients receive spinal anaesthesia on their first insertion, where manual 
examination of the vaginal vault and rectum is done simultaneously. Manual 
examination is done to establish the following (Viswanathan & Petereit, 2007): 
 the size of the tumour, 
 the size of the cervix, 
 to assess the visible vaginal and cervical extent of the disease and 
determine the visibility of the cervical ostium, 
 the nature of the tumour, i.e. whether it is exophytic, endocervical, 
symmetrical or eccentrically placed, 
 the extent of the disease in the vagina, e.g. are the fornices palpable, 
 to assess if EBRT caused fibrosis or narrowing of the vagina that will 
probably further deteriorate with brachytherapy, 
 to assess if the vagina is large enough to allow sufficient packing, 
 the visibility and palpability of the ostium, 
 mobility of the uterus, 
 the state of the uterus, i.e. anteverted or retroverted, 
 to determine the curvature of the tandem that will optimize the uterine 












The radiation oncologist takes into account all of the above factors before the 
insertion of radiation sources in order to determine the best applicator to use.  
With the patient in the lithotomy position, patient movement is minimised by 
strapping the legs to holders on the treatment couch. Magnification rings or 
magnification reconstruction apparatus are put on the surface of the patient’s 
skin and then an applicator of choice is inserted into the patient. A Foley 
catheter with a balloon is inserted into the bladder via the urethra and 7 ml of 
contrast liquid is allowed into the balloon. A rectal retractor and gauze packing 
are placed in the vaginal vault under the applicator (when feasible). These 
devices serve to push the rectum away from the radiation. 
2.8.1 Imaging 
When satisfactory patient setup geometry has been achieved, a set of oblique 
orthogonal, AP and lateral x-rays are obtained in order to plan the insertion. 
The image typically shows the whole system including bony anatomic 
landmarks. The images and the geometry of the implant are critically analyzed 
and the process repeated if the images are not satisfactory. If a CT scan is 
used, it is possible to generate lateral and AP digitally reconstructed 
radiographs (DRR’s). A Foley catheter with balloon is inserted into the bladder 
and filled with fifty millilitres of contrast before scanning. The radiation 
oncologist can scroll through the CT images, which makes identification of 
perforations possible. Detection of a perforation warrants removal of the 
applicator, which can then be reintroduced into the cervix using ultrasound 
guidance to guarantee positioning in the centre of the uterus. The use of CT 
scans enables delineation of the bladder, rectum, sigmoid and tumour volume, 
which facilitates assessment of dose to these structures using dose volume 
histograms (DVH) (Viswanathan & Petereit, 2007). Magnetic Resonance 
Imaging (MRI) enables outstanding soft tissue visualization and contrast, 
which facilitates accurate contouring of the OARs and the tumour volume and 
is recommended (Gerbaulet, et al., 2005) and used at some centres for 
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related to cost and large patient volumes limit the availability and accessibility 
of MRI to most patients at most centres worldwide. 
2.8.2 Dose Specification 
In the early 1900s when brachytherapy commenced, there was a lack of 
comprehensive knowledge about the biological effects of treatment using 
radiation. However, beginning from the 1920s and early 1930s, better 
understanding and new scientific methods were developed and implemented, 
particularly at the Radiumhemmet in Stockholm (Stockholm system in 1929, 
1935) and at the Curie Foundation in Paris (Paris system in 1929). In the 
1930s at the Christie Hospital, Manchester, Todd and Meredith modified the 
Paris system and established the most widely used brachytherapy technique 
in the world (Godden, 1988). Todd and Meredith calculated the dose to 
various regions of the pelvis in roentgen, as opposed to calculating the dose 
in milligram hours (mgh) of radium. They defined a series of points that are 
anatomically similar from patient to patient, at which the exposure dose should 
be stated and measured. The points were chosen in such a way that they 
were independent of small alterations in applicator position.  
Table 2.2 Tandem and ovoid dose points ( (ICRU-38, 1985) 
Point A (right or left) 2 cm along the axis of the central tube from the lower end and 2 
cm from it laterally, i.e. for the ring and tandem applicator, point A 
is positioned at 2 cm away from the central tandem and 2 cm 
above the ring. 
Point B (right or left) 2 cm superior to the ring or ovoid and 5 cm laterally from the 
midline. 
ICRU Rectum 5 mm below the vaginal wall/speculum, radiopaque gauze 
packing, rectal retractor or most posterior ovoid position. 
ICRU Bladder 
 On Anterior-Posterior radiograph - center of Foley bulb, 












Todd’s work proved that the limiting radiation dose was the dose to the region 
where the uterine vessels cross the ureter, i.e. the ‘paracervical triangle’, and 













Fig 2.3: Localization of bladder and rectum points from (ICRU, 1985)  
 
This gave birth to the designation of Point A for specifying dose and the 
system of radiation sources planned was intended to deliver a constant dose 
rate to identified points close to the cervix, regardless of any difference in the 
size and shape of the uterus and vagina. At first this point was defined as 
lying “2 cm lateral to the uterine canal and 2 cm from the mucous membrane 
of the lateral fornix of the vagina in the plane of the uterus” (Godden, 1988). 
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from the lower end and 2 cm from it laterally, i.e. for the ring and tandem 
applicator, point A is positioned at 2 cm away from the central tandem and 2 
cm above the ring. Another reference point, Point B, was also formulated and 
was defined as being 5 cm away from the midline and 2 cm from the mucous 
membrane of the lateral fornix, see table 2.3 and fig 2.3 earlier, and figs 2.4 
(a) and (b) below.  
 
           
Figure 2.4: (a) Manchester/Fletcher and Fig 2.4 (b) Cylindrical applicator 
(redrawn from (Gerbaulet, et al., 2005)) 
Point B was formulated in order to determine the dose in the region close to 
the pelvic wall near the obturator node and assess the lateral spread of the 
effective dose (Godden, 1988). 
2.8.3 Computerised Treatment Planning 
Treatment planning and dosimetry in brachytherapy is not at the same level 
as that of external beam therapy. (Williamson, 1988) researched and reported 












have lagged behind those in external beam therapy. The reasons he gave are 
listed below: 
- Difficulties were experienced in defining the dose specification of the 
target volume and organs at risk, 
- There was lack of resources and problems of artefacts produced when 
CT images were acquired with applicators inside the patients, 
- High dose gradient in brachytherapy, 
- The heavy dependence on point dose calculations derived from 
radiographic information rather than from volumetric prescription for 
dosimetric calculations, 
- The absence of calculation algorithms which incorporate accurate 
corrections for tissue inhomogeneities, inter-source effects and 
complex shielding applicators, 
- The reliance on retrospective clinical data for prescriptive and 
acceptable tolerance doses. 
However, accuracy in brachytherapy has advanced in recent years owing to a 
renewed interest in brachytherapy dosimetry and also due to the following 
(Venselaar, et al., 2004): 
- The availability of remote afterloading which uses HDR, LDR and PDR 
sources, 
- Increased accessibility of CT scan data, 
- Volume defi ition using MRI, 
- Dose calculation using Monte Carlo techniques, 
- Availability of real-time dosimetric and biologic optimisation, 
- Use of low energy gamma ray sources. 
Specification of source strength in treatment planning systems is 
internationally recommended to be in units of reference air kerma rate, KR, 
which can be traced to an Accredited Calibration Laboratory in 
documentation. Calculations within the treatment planning system (TPS) rely 
on interpolations from a table of dose in water stored for each source (i.e. a 
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symmetry and that the space in which the calculations are made is water 
equivalent. The tables do not take into account the different heterogeneities 
and modifications for inter-source effects and applicator attenuation. The 
sources and dose points are reproduced in 3D space and then the co-
ordinates are transposed into the dose rate table co-ordinate system. 
Interpolation and renormalization is done and the dose at a particular point is 
obtained by summation of contributions of all individual sources, i.e. all the 
dwell positions of one source. Most TPS systems use dose rate tables derived 
from the American Association of Physicists in Medicine Task Group Report 
No. 43 (Nath, et al., 1995), AAPM TG 43 formalism. 
2.8.4 AAPM TG 43 Formalism 
This formalism considers the dose distribution to be cylindrical. A polar co-
ordinate system with the source centre as the origin and an angular origin in 
the longitudinal axis of the source describes the geometry as shown below. 
 
 
Fig 2.5 Radial and rectangular co-ordination with reference from the 













The dose at point P(r, ) can be written as: 
                                   (   )        
 (  )
 (    )
 ( ) (   )                    . . . (2.24) 
where, 
  is the radial distance from the source’s centre in the same plane as 
the axis; 
   is the polar angle; 
    is the air kerma strength; 
   is the dose rate constant; 
   is the exposure time; 
  (   ) is the geometry factor which takes into consideration the spatial 
distribution of the active material in the source; 
  (   ) is the anisotropy function which gives the angular dependence 
of absorption and scatter of the photons inside the core and 
encapsulation; and 
  ( ) gives the radial dose function which incorporates the distance 
dependence of absorption and scatter in water along the transversal 
axis, i.e. for the angle   =   ⁄ . (     ) is an angle situated at 1 cm away 
from the centre of the source, i.e. for    = 1 cm and    =   ⁄ . 
   is the dose rate constant and is the dose rate to water,1 cm to the 
transverse axis of a unit air kerma strength source in water,                                                            
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 ̅̅ ̅̅ ̅̅ ̅̅ ̅̅
is the term representing the ratio of mass energy absorption 
coefficients in medium m and in air, 
  ( ) amalgamates the attenuation of primary photons, together with 
effects of scattered photons in the medium, 
  (     ) is a geometry factor that gives the spatial distribution of the 
active material in the source, 
  ( ) gives the dose gradient along the axis of the source and together 
with effects of absorption and scatter in water.  
                                          ( )   
 ( )
 (  )
                                                   (    ) 
The term  ( ) is also affected by filtration of photons by the encapsulation 
and source materials (Nath, et al., 1995). 
2.9 Adverse Side Effects 
The most common side effects after treatment of gynaecological malignancies 
usually involve the bowel and urinary tract. Table 1.1 gives a summary of the 
acute and late complications that may occur in patients after receiving 
radiotherapy as treatment for gynaecological cancers. 
Radiotherapy-induced toxicity may either be attributed to brachytherapeutic 
techniques and doses or other radiotherapy independent factors, i.e. surgery, 
concomitant chemotherapy, diabetes, HTA, etc. (Gerbaulet, et al., 2005). This 
research will consider those factors which are attributed to irradiation. The 
following factors influence the occurrence of complications in radiotherapy 













1. Total Dose: The total radiation dose, i.e. by external beam irradiation 
of the whole pelvic region and by intracavitary brachytherapy, greatly 
influences the occurrence of side effects (Perez, et al., 1991) and 
(Perez, et al., 1999). There is a significant increase in the occurrence of 
side effects when total doses of greater than 80 Gy are given. 
2. Volume: Occurrence of complications in combined external irradiation 
and intracavitary brachytherapy is also closely related to the total 
irradiated volume. There is a considerable increase in the volume 
receiving more than 60 Gy when patients receive more than 30 Gy of 
external beam radiotherapy (Esche, et al., 1987).   
3. Brachytherapy technique: It was discovered that the use of certain 
applicators was associated with a higher likelihood of occurrence of 
complications (Perez, et al., 1999). However, techniques were 
developed (Barillot, et al., 2000) and can now be used to reduce 
complications after receiving radiotherapy treatment for gynaecological 
cancers. 
4. Dose rate: It has been argued by many authors that low-dose rate 
brachytherapy produces better results and less complication rates than 
high-dose rate brachytherapy (Haie-Meder, et al., 1993) and (Newman, 
1996). However, this issue has been a source of controversy up to now 
(Stewart & Viswanathan, 2006). (Stewart & Viswanathan, 2006) 
suggest that LDR may be preferable for large, bulky tumours at the 
time of brachytherapy, while on the other hand, they recommend that 
satisfactory tumour shrinkage should have occurred before HDR is 
administered and cautious monitoring of dose to normal tissues should 
be done. An extensive study by (Wang, et al., 2010) concluded that 
“there was no significant difference between HDR and LDR when 
considering overall survival, disease-specific survival, relapse-free 
survival, local control rate, recurrence and metastasis and treatment 
related complications for patients with clinical stages I, II and III. 
Therefore we recommend the use of HDR for all clinical stages of 
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2.10  In-vivo Dosimetry 
Radiotherapy aims to administer a lethal dose to the primary tumour volume 
(PTV), while surrounding normal tissue and organs receive the least possible 
dose. Numerous experiments and clinical studies have shown that small 
changes in dose of between 7 % and 15 % can reduce local tumour control 
(Dutreix, 1984). The International Commission on Radiological Units (ICRU, 
1976) recommends that the difference between the prescribed and delivered 
dose should not exceed 5 % in order to maintain local tumour control. 
Uncertainties in the dose delivered in radiotherapy arise from each step 
executed in the treatment process, i.e. from treatment planning itself until 
treatment is administered. Therefore, the American Association of Physicists 
in Medicine (AAPM) (Kutcher, et al., 1994) and (ICRU, 1976) recommend  in-
vivo dosimetry to be done on patients. 
In-vivo dosimetry is a tool to measure the radiation dose delivered to patients 
during radiotherapy. The aim of in-vivo dosimetry is to compare dose 
measurements with the dose values specified by the radiation oncologist and 
the dose values calculated by the TPS. This exercise is done to verify that: 
-  ‘what is prescribed is what is delivered’, 
- ‘ what is treated is that which is intended to be treated’, 
In other words, in-vivo dosimetry serves to ‘verify’, 
i. output and performance of the treatment equipment ; 
ii. patient set-up; 
iii. the dose calculation algorithm and to determine the effect of 
changes in body shape, size and density on the dose calculation 
procedure; 
In-vivo dosimetry is not only intended to verify the dose delivered to the target 
volume, but also to monitor dose to organs at risk (e.g. bladder, rectum, 












when using non-standard source-to-skin distances in external beam 
radiotherapy) (Podgorsak, 2005). Practising in-vivo dosimetry helps to: 
i. decrease the risk of occurrence of serious radiation accidents; 
ii. guarantee that patients are treated as planned; 
iii. comply with laws and regulations governing the practice of 
radiotherapy in South Africa, i.e. The Hazardous Substances Act, 
1973 (Act 15 of 1973) and Regulations (No R1332 of 3 August 
1973) governing the safe use of medical x-ray equipment in South 
Africa. 
2.10.1 In-vivo Dose Measurement Techniques 
Semiconductor detectors (silicon diodes) and thermoluminescent detectors 
(TLDs) are the most commonly used types of detectors for in-vivo 
measurements. There is a wide variety of dosimetry systems that can also be 
used to perform in-vivo measurements, e.g. film, gel dosimeters, ionization 
chambers, electronic devices (e.g. metal oxide semiconductor field effect 
transistors (MOSFETs)) and alanine (Podgorsak, 2005). However, in this 
research, silicon diodes were found to be best adapted to perform 
intracavitary in-vivo dose measurements and therefore were used in this 
research.  
2.10.2 Silicon Diodes 
Characteristics of silicon diodes that make them the detector of choice for in-
vivo dosimetry include high spatial resolution, high sensitivity, absence of 
external bias, small size and the utility of making real-time measurements 
(Podgorsak, 2005). Silicon’s density and the relatively low average energy it 
needs to make a carrier pair produces radiation induced current densities 
approximately 18,000 greater than those produced in air. This means that 
small volumes of silicon (typically 10-2  10-1 mm3) generate a considerable 
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There are two types of silicon diodes, i.e. n-type or p-type silicon, that rely on 
minority carriers being holes or electrons respectively (Huyskens, et al., 
2001). Fig 2.6 below shows how a p-type silicon radiation detector works. At 
the junction between the separate p-type and n-type regions, there is a lack of 
free charge carriers. A potential of approximately 0.7 V exists over the 
depletion area when the detector is made to operate at zero external voltage. 
This causes the charge carriers produced by the radiation to be carried away 













Figure 2.6: Schematic drawing of a p-type silicon radiation detector 
(Huyskens, et al., 2001). 
Electrostatic potential   0.7 V 
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The diode is asymmetrically doped, i.e. there is heavier doping of the n-type 
region compared to the p-type region. This means that the charge flow 
produced by the irradiation almost entirely consists of electrons (in a n-type 
diode the induced charge flow would mostly consist of holes).  
The diode signal is reduced as a result of some electrons being trapped by 
defects in the crystal lattice. In n-type diodes, holes are more susceptible to 
be trapped in crystal lattice defects and this greatly influences the detection 
capacity of the diode (Huyskens, et al., 2001). 
The lifetime of the charge carriers and the quantity of the recombination 
centres in the crystal determine the sensitivity of the detector. Diode detectors 
have small sizes and high spatial resolution which make them very useful in 
measuring dose in steep dose gradient regions, for instance, the area around 
a brachytherapy source. Below are some of the desirable characteristics of 
diode detectors (Wilkinson, 2010): 
i. Small size and weight. 
ii. Mechanically stable and generally having good reproducibility. 
iii. Provide real–time dose read outs. 
iv. Diode production costs are relatively low.  
v. Detectors show little radiation field perturbation. 
Diode detectors are very useful in in-vivo dosimetry, but they have the 
following limitations (Wilkinson, 2010): 
i. Diodes exhibit an angular (directional) dependence which is 
dependent on the shape and size of the diode, and how the diode is 
set up relative to the direction of the source of radiation. 
ii. Diode detectors show a temperature dependence, i.e. diode 
response varies with temperature. 
iii. Diode detectors also show energy dependence, i.e. the diode 
response varies with energy of the incident radiation. 
iv. Diode detectors exhibit reduced sensitivity with accumulated dose 
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Diode detectors have been in use clinically in gynaecological 
brachytherapy for some time now and (Wäldhausl, et al., 2005) carried out 
an extensive in-vivo dosimetry study using diodes involving 55 ICBT 
applications on patients. Diodes used in that study, i.e. PTW diode probes, 
are identical to the diodes that were also used in this study. Bladder and 
rectum doses computed by the TPS and doses measured by the diodes 
showed differences ranging from -27 % to +26 % for the bladder and -31 
% to +90 % for the rectum. Another study carried out by (Hassouna, et al., 
2011) reported that the ratio of the ICRU reference point dose to the diode 
dose was 1.2 ± 0.5 for the bladder and 1.7 ± 0.5 for the rectum. In the 
study by (Wäldhausl, et al., 2005), they also evaluated the characteristics 
of the PTW diodes for reproducibility, linearity, angular, energy and 

























CHAPTER 3 IN-VIVO DOSIMETRY MEASUREMENTS 
3.0 Introduction 
HDR Brachytherapy has experienced rapid technical advances in treatment 
planning and dose delivery systems over the last decade. However, the 
accuracy of these systems still requires independent checking to prevent 
potential dose errors (Qi, et al., 2007). The need and necessity for in-vivo 
dosimetry was discussed in the previous chapter and this chapter will describe 
how an in-vivo dosimetry system was set-up for use during HDR 
brachytherapy for gynaecological malignancies at Groote Schuur Hospital, 
Cape Town. 
3.1 Calibration and Reference Dosimetric Quantity of a HDR 
Source 
Source strength of a brachytherapy source is expressed in terms of: 
i. Activity of the source, A; 
ii. Apparent activity; 
iii. Equivalent mass of radium in milligrams; 
iv. Air kerma strength , Sk. 
Air kerma strength is the American Association of Physicists in Medicine 
(AAPM) recommended reference dosimetric quantity. Sk is derived from 
exposure rate ( ) obtained at 1 m distance from the source in free air (Khan, 
2010). 
                                                   Sk = Ḱ                                                . . . (3.1) 
where the air kerma rate Ḱ, is obtained at a reference distance     , and 
    = 1 m. 192Ir sources are calibrated in terms of exposure rate at 1 m in 
open-air scatter-free geometry at primary standard dosimetry laboratories 
(PSDLs). Clinical calibrations for brachytherapy sources are supposed to be 
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(SSDLs). Calibration of  brachytherapy sources in hospital settings is 
performed in well chambers with calibration factors obtained at PSDLs or 
SSDLs. In this study, the 192Ir source was calibrated in a well chamber and in 
a standard in-air jig. The measured values are compared with the ‘decayed’ 
values of the reference source air kerma strength provided on an 
accompanying source calibration certificate, measured at the secondary 
standard laboratory at PTW-Freiburg, Germany.  
Stability Check 
A stability check of the Farmer type ionization chamber was performed in a 
long life Strontium-90 source.  
Tolerances 
The tolerance for the stability check is 1 %.  Deviations of check values 
beyond 1 % warrant investigation and documentation.  
3.1.1 In-Air Calibration of 192Ir Sources 
The in-air measurement technique determines the source strength in terms of 
the air kerma rate at a certain distance, from which the reference air kerma 
rate is then worked out (Venslaar, et al., 1994). In this study a 0.6 cc PTW 
Farmer ionisation chamb r, type 31002 and accompanying electrometer, 
PTW UNIDOS, with calibration factors traceable to PTW-Freiburg, Germany, 
were used to calibrate the 192Ir source. Recommendations for the calibration 
of 192Ir HDR sources (Venselaar, et al., 1994) urge the use of a thimble 
chamber together with its build-up cap during source calibration. The build-up 
cap serves to contain contaminating electrons emanating from the 192Ir source 
encapsulation. The in-air calibration was done in a dedicated jig which 
provides reproducible repositioning of the ionisation chamber and source 













The measurements were done at a distance of 100 mm. Time intervals of 600 
s were used to obtain the measurements. The reference air kerma rate Ḱ 
(cGy.h-1)  was obtained using the following formulas and relationships. 
                                               
       
 
 
                                           . . . (3.2) 
where  
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Figure 3.2: In-air calibration setup at Groote Schuur Hospital, Cape Town 
where  
           is the corrected reading from the instrument for the time period t; 
                is the uncorrected reading from the instrument; 
   is the air temperature correction factor as a function of the reference  
temperature at which the calibration factor Nk was determined; 
   is the air pressure correction factor as a function of the reference air 
pressure at which the Nk was determined; 
                is the air humidity correction factor; 
      is the ion recombination factor;                                            (1.000)1 
      is the correction factor for polarity effects;                            (1.000)1 
    is the correction factor that takes into account the dose non-
uniformity over  the chamber wall and is calculated from data given by 
(Kondo & Randolph, 1960);                                                         (1.006) 
Nk (µGy per unit reading) is the air kerma calibration factor for the 192Ir 














                                                                                           . . . (3.4)                                      
    is the correction factor for source transport time for (t > 600 s or 
0.1667 h)              (1.0) 
    is the correction factor for room scatter for a wall to chamber 
distance of 0.5 m or more                                                             (0.999) 
and where, 
d is the source-to-chamber axis distance for the jig relative to the 1 m 
reference distance.                                                                       (0.100) 
t is the total exposure time (in hours) of the measurement with the 
source at its position in the catheter.                                         (0.1667) 
1 Are values obtained for the specified measurement conditions and may 
change under different measuring conditions. Performing the measurements 
at a distance of 100 mm allows omission of the effect of air attenuation since it 
amounts to a very small correction when applied to measurements done at 
such small distances.  
The air kerma strength Sk’  is then calculated from the air kerma rate from the 
relationship shown below, 
                                                                   (cGy/h m
2)                   . . . (3.5) 
Where   is the air kerma rate at a reference distance      ,      = 1 m. 
The air kerma strength is the standard measurement used to specify the 
source strength in source ordering, dose computation, treatment planning and 
implant description (Bochud, et al., 2005). 
3.1.2 Calibration of 192Ir Sources in a Well Chamber 
Performing relative source strength measurements of 192Ir sources in a Well 
chamber, i.e. the redundancy standard, is standard practice at the hospital. 
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accompanying calibration certificate (reference), measured at the SSDL at 
Nucletron, in the Netherlands. The well chamber used at the hospital is a 
PTW Well chamber type 077.091 shown in Figure 3.2 (a) below.   
This is a dedicated well chamber for calibration of 192Ir sources. A typical 
schematic diagram of a well-type chamber is shown in Figure 3.3 (b). 
The source is stepped-into the well chamber at specified distances and 
constant time intervals to locate the highest reading point. Several readings 
are taken at this point and the average reading is used to calculate the air 
kerma rate as shown in equation 3.6. 
 















                                                          
       
 
                                     ... (3.6) 
 
where, 
       is the reference air kerma rate of the source; 
           M is the electrometer reading; 
 Nk is the calibration factor of the well chamber; 
 ftr is the correction factor for source transport time; 
t is the exposure time of the measurement with the source at the 
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Since the well chamber is a sealed chamber, there is no need for temperature 
and pressure corrections. The air kerma strength is calculated from the air 
kerma rate using equation 3.2 above. 
3.1.3 Uniformity with Vendor Reference 
Reference air kerma values obtained at the hospital are compared with the 
vendor-supplied values. A deviation within 3 % between the two values is 
considered as acceptable and the vendor reference air kerma values are used 
in determining patient treatment times. If the discrepancies are more than 3 
%, investigations to find possible reasons are made and if the discrepancies 
remain, then a report is made to the vendor.  
 
3.1.4 Uniformity of Measurements at the Hospital 
For redundancy measurements done at any time at the hospital, the air kerma 
strength measured using the local standard is compared with the redundancy 
standard. The vendor reference value is used without investigation for 
differences in values less than 3 %. If the difference is greater than 3 %, then 
this warrants investigation. 
3.2 Rectum and Bladder Dosimeters 
Semiconductor dosimeter probes manufactured by PTW-Freiburg were used 
to measure doses received by the bladder and rectum in this study. The 
semiconductor diodes are covered with waterproof encapsulation and are 
custom made for ease of insertion into the organs. 
The rectum probe (T9112) has five independent diodes that measure the dose 
at different points along the rectum. T9113 is a single diode bladder probe that 
is used to measure doses in the bladder. 
The diodes generate a current when exposed to ionizing radiation. A 
dosimeter (PTW Vivodos Electrometer) connected to the probes measures 
the current and converts the current to dose. Online measurements for 
individuals are viewed and stored on a computer using a software program 













Figure 3.4 (a) : T9112 rectum probe 
 
 
Figure 3.4 (b) : T9112 rectum probe 
 
 
Figure 3.4 (c) : T9113 bladder probe 
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3.3 Calibration of Semiconductor Probes 
Calibration of semiconductor probes is carried out in a custom-made 
afterloading cylindrical PMMA calibration phantom (type 9193), manufactured 
by PTW-Freiburg, Germany. There is a central slot for placement of the 192Ir 
source and on a circle of radius 8 cm; it has four holes that are situated 2 cm 
from the edge of the phantom.  
 














Figure 3.5 (b): PTW Type 9193 Phantom connected to Flexitron Remote 
Afterloader 
where, 
  Bp is the bladder probe,  
Sc is the 192Ir source catheter,  
Rp is the rectum probe,  
Fc is the PTW Farmer chamber, and 
D is the dummy plug.  
These holes are positioned at 0°, 90°, 180° and 270° into which detectors, i.e. 
a thimble ionization chamber, bladder and rectum probes, are placed using 
appropriate plugs as shown in Figs 3.5 (a) and (b). The phantom also 
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brachytherapy sources. Closing unused holes in the phantom during source 
calibration achieves equal scatter of radiation within the phantom.  
Calibration of the semiconductors is done against the redundant thimble 
chamber with calibration factors traceable to the PTW-Freiburg SSDL in 
Germany. The thimble chamber was calibrated in a Cobalt-60 beam and a 
100 kV beam.  
3.3.1 Air Kerma Strength Calculation from Air Kerma 
Measurements 
Dose measurements performed by a thimble chamber calibrated in terms of 
air kerma in Cobalt-60 radiation is given by: 
                                 {             }                                     . . . (3.7) 
                                           = 0.00760 
where, 
Nk is the air kerma calibration factor for Cobalt-60 radiation [µGy/readout unit]; 
ka p is the perturbation factor from air to PMMA environment (ka p = 1); 
kr is the inverse square law correction factor (kr =     )⁄ 2 = 0.0064; 
kzp is the geometry correction factor for the PTW - type 9193 cylindrical PMMA 
phantom;  
kzp = 1.187 ± 0.012 (Bochud, et al., 2005, p. 14). kzp also contains the volume 
correction factor for the PTW 31002 thimble chamber at a distance of 8 cm;  
kλ is the correction for the instrument response in 192Ir radiation. kλ  is 
calculated from the instrument specifications. For an instrument with a 
response of 1.00 in 60Co radiation, kλ is the extrapolated response calculated 
between 60Co and the highest x-ray energy available assuming the mean 












kpT is the air density correction factor = (
            
      
 
       
 
), where Tph is the 
phantom temperature [°C] and p is the air pressure [hPa]; 
kƮ is the time correction factor (
  
 
), where   [min] is the measurement time; 
{             } = 0.00760 for all measurements made in the phantom 
(Bochud, et al., 2005). 
3.3.2 Air Kerma Calculation from Absorbed Dose to Water 
Measurements 
An ionization chamber calibrated in absorbed dose to water in 60Co radiation 
can also be used to determine the air kerma strength Sk [µGy/hm2]. 
                 {
 
     
 
(    ⁄ ) 
(    ⁄ ) 
               }                             . . . (3.8)  
                  = 0.00684 
where, 
M is the instrument reading [readout unit]; 
Nw is the absorbed dose to water calibration factor performed in 60Co 
radiation; 
kw→p is the perturbation factor from water to PMMA environment (kw→p =1.00); 
(µen/ )a and (µen/ )w  are the mass energy absorption coefficients for air and 
water respectively. [(µen/ )a / (µen/ )w = 0.899]; 
gw is the relative energy lost through bremsstrahlung (gw = 0.001). 
 
All the other factors are the same as given in equation 3.7 above (Bochud, et 
al., 2005). 
 
The 192Ir source was calibrated in the phantom using the two methods 
mentioned above and the average of three measurement runs was taken and 
compared with vendor supplied reference air kerma strength (see source 
certificate in Appendix 1). The result was found to be within 3 % of the 
standard and was considered as a valid air kerma strength value for that date.  
A complete in-vivo dosimetry measurement set consists of a Well chamber, 










   
 53 
checking source positioning), Vivodos AL Dosimeter, MultiSoft Software, 
single semiconductor T9113 bladder probe, five-diode semiconductor T9112 
rectum probe, and a detector connection box to connect the detectors to the 
dosimeter. Since this system was brand-new and was set up for the first time, 
the semiconductor probes, i.e. the bladder and rectum diodes had no 
calibration factors. The MultiSoft software program allows calibration of the 
semiconductor probes and enables viewing and documentation of dose 
measurements on a computer monitor.  
3.3.3 Calibration using MultiSoft Software 
The MultiSoft software was installed on one of the treatment planning 
computers. The semiconductor probes had no calibration factors and they had 
to be cross-calibrated using an ionization chamber. The bladder and rectum 
probes, as well as the source catheter and a dummy plug were placed in the 
T9193 phantom as shown in Fig 3.5 (b). The T9193 phantom places the 
source, bladder diode, rectum diode number 3 and the active measuring 
volume of the ionization chamber at the same measuring point. The detectors 
were exposed to a previously determined (reference) dose or air kerma value. 
The MultiSoft program was set to calibration mode, the dose was measured 
for the specified time, and calibration factors for the bladder diode and central 
rectum detector were computed. The software program automatically takes 
into account the differences in distance from the source to the other rectum 
diodes and simultaneously computes the respective calibration factors for the 
diodes. These calibration factors were then saved into the software program 
and computer. The semiconductor detectors were then ready to perform dose 
measurements. The detectors were exposed to the reference dose and the 
dose measured by the bladder diode and central diode of the rectum probe 
was compared with the dose registered by the ionization chamber. The 
calibration procedure was repeated until the dose registered by the ionization 
chamber, bladder diode and central diode of the rectum probe were identical. 
Identical dose measurements of the respective detectors confirm the 












The calibration factors were saved for future use and at this point the bladder 
and rectum probes were ready for use in patients. 
The calibration procedure is a continuous exercise repeated periodically with 
time since the semiconductor detectors change their characteristics after 
cumulative exposure to high radiation doses. The change in calibration factors 
is a function of applied dose and energy and occurs gradually over time with 
increased use of the detectors.   
3.3.4 Pilot Study in Phantom 
After the bladder and rectum probes were calibrated, a pilot study was carried 
out in a Rando phantom. The Rando phantom provides an adequate radiation 
scatter medium that is tissue equivalent, satisfying ICRU Report No.44 
requirements (ICRU-44, 1989).  
Method 
 The Rando phantom was set up together with a reconstruction box on 
a patient treatment bed. 
 A standard Smit applicator (5 cm active length) and bladder probe were 
inserted into two separate holes in the phantom as shown in Figs. 3.6 
(a) and (b) above. 
 Anterior-posterior and lateral radiographs were taken and the central 
point of the bladder diode was marked as a dose control point on the x-
ray images.  
 The radiographs were scanned into the TPS and a 2 Gy dose was 















 The TPS computed the dose that the bladder was going to receive and 
the plan was transferred to the treatment machine for activation of an 
exposure. 
 The Rando phantom was irradiated with a prescribed dose of 2 Gy to 
point A and the dose registered by the bladder probe was recorded. 
 The dose measured by the bladder diode in Rando was compared with 
the TPS calculated value and was found to be within 3 %. 
 
Figure 3.6 (a) Setup for dose 
measurement in Rando phantom 
(front view) 
                   
Figure 3.6 (b) Setup for dose 
measurement in Rando phantom 
(side view) 













Figure 3.7: Flexiplan treatment plan for a radiation dose of 2 Gy to point 
A in Rando 
The method was repeated a number of times with the bladder probe at 
different positions. The results obtained were within 3 % of each other and this 
confirmed that the bladder probe was calibrated correctly. The rectum probe 
could not fit into the diode holes in the Rando phantom. However, from the in-
phantom source and detectors calibration procedure, it was concluded that 
the rectum probe was also calibrated correctly.  
 
3.4 Dose Measurements in Patients 
 
3.4.1 Background 
The process of setting up a patient for treatment, identification and selection 
of appropriate applicators for use and dose prescription for the ICBT 
procedure is discussed in the previous chapters. Currently at Groote Schuur 
Hospital (GSH), Flexiplan, a treatment planning software (TPS) program, is 
used to compute doses received by the bladder and rectum during ICBT. The 
procedure for obtaining the dose to the OARs is as follows: 
 Contrast liquid is injected via a catheter into a Foley balloon inserted in 
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rectum from the applicator and serves as a rectal marker) is placed 
inside the vaginal cavity. 
 Anterior-posterior and lateral orthogonal radiographs are taken with the 
applicator and markers in position. 
 A Radiation Oncologist identifies the International Commission on 
Radiological Units Report No. 38 (ICRU-38, 1985) and American 
Brachytherapy Society (ABS) (Nag, et al., 2000) dose reference points 
for the bladder and rectum and marks the points on the radiographs.  
 The marked radiographs are then scanned and digitized into the 
Flexitron TPS program on a treatment planning computer.  
 The TPS will produce a dose distribution of the setup showing the type 
and size of applicator used, as well as the position of the ICRU and 
ABS reference points relative to the sources of radiation and the 
alignment of the applicator in the cavity. The ICRU reference point A is 
prescribed to receive 100 % of the dose and the bladder and rectum 
reference points should each receive at most 70 % of the prescribed 
dose.  
This method is the only method that is in use to obtain values of the dose 
received by the rectum and the bladder during gynaecological brachytherapy 
at GSH. However, previous investigators recommend that it is good practice 
to carryout in-vivo dosimetry measurements to complement the dose 
computations by the TPS (Hassouna, et al., 2011) and (Wäldhausl, et al., 
2005). 
3.4.2 In-vivo Measurements in Patients 
After successful commissioning of the in-vivo dosimeters (a detailed 
procedure of commissioning of in-vivo dosimeters was done by (Wilkinson, 
2010)), seeking and obtaining ethics approval, a protocol was followed in 
selecting participants and carrying out the study. The main aim of the study 













In order to achieve this, additional to the protocol of using ICRU (ICRU-38, 
1985) and ABS (Nag, et al., 2000) dose reference points for computing dose 
received by the rectum and bladder during ICBT described in section 3.5.1 
above, the following procedures were done: 
 The bladder and the rectum diodes were marked as dose control 
points on the orthogonal images. 
 The TPS computed dose that was supposed to be registered by the 
semiconductor detectors and the approved treatment plan was 
transferred to the treatment computer and machine for treatment. 
 The patient was treated and the dose received by the bladder and 
rectum was measured by the in-vivo dosimetry system. 
 The measured in-vivo measurements were recorded and compared 
with the TPS computed doses. 
 
 
Figure 3.8: A standard treatment plan for a 30 mm diameter ring - 70 mm 

















Figure 3.9: A typical cylinder and tandem combo applicator showing 
how coordinates for the diode measuring points are obtained 
3.4.3 Dose Measurements in a Water phantom (In-vitro 
Measurements) 
The treatment applicator setup was replicated in a water phantom based on 
previous work that was done to analyse rectum doses during HDR 
brachytherapy (Huh, et al., 2007). Water was chosen to be the perfect tissue-
equivalent material and a motorised PTW 3D MP3 water tank was used as the 
phantom satisfying the definition of a phantom, i.e.  
“A body phantom is generally composed of various tissue substitutes 
simulating the human body or a part of the body with respect to size, shape, 
position, mass density and radiation interaction”, (ICRU, 1989).  
The bladder and rectum diode probes were separately mounted and 
positioned in the water tank using the motorised apparatus usually used for 
positioning ion chambers in calibration of external beams (see Figs 3.10 
(a),(b) and (c)). Distances between the diodes and particular applicator 
‘reference’ points were measured from AP and lateral x-ray images on the 
TPS using a calibrated ruler. Diode measuring-point coordinates were used to 













tank. A PTW MP3 3D water tank with 0.1 mm measuring capability functioned 
as a phantom in which dose measurements were made.   
The dimensions of the PTW MP3 tank are 600 mm x 600 mm x 408 mm = 
0.14688 m3 and this is equal to a full patient radiation scatter volume. 
Therefore, the MP3 tank was filled up every time in-vitro measurements were 
made. The bladder and rectum probes were secured to custom-made acrylic 
rods using ordinary thin masking tape to provide rigidity and ease of 
positioning. The motorised ruler on the MP3 tank was used to position the 
bladder and rectum probes.  
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Figure 3.10 (b): Cylinder and tandem combo setup in PTW MP3 tank 
 













The acrylic adapter served to accurately position the applicator and minimized 
additional radiation scatter that was produced in the measuring setup. There 
were no x-ray radiographs taken in this procedure and positioning of the 
diodes was critical to reproducing the patient treatment setup in the water 
phantom.  
Distances between diodes and particular applicator ‘reference’ points were 
measured using calibrated rules in the x,y and z directions from the AP and 
lateral x-ray images on the TPS as shown in Fig 3.9 above.  
For in-vitro measurements, the ‘treatment’ position of the applicator in water 
was regarded as the origin i.e. (0, 0, 0 ).For each diode position, x,y,z 
coordinates were reproduced in water by moving the applicator in x,y,z 
directions to position the diode in water. Diode ‘measuring-point’ coordinates 
were used to position the bladder and rectum probes relative to the applicator 
in the water tank. 
When a satisfactory setup was achieved in the water phantom, a specified 
patient dose was delivered and the dose measured was recorded. The 
procedure was repeated several times in water for each patient treatment and 
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CHAPTER 4 RESULTS 
4.1 Measurements 
In calibrating the diode probes used for all measurements in the research, a 
traceable reference dosimetric quantity had to be used to provide reliable 
traceability reference for the calibration factors of the diode probes. The 
source air kerma strength was used as the reference dosimetric quantity that 
provided reference to the calibration of the source strength done at the 
Secondary Standard reference laboratory at Nucletron in the Netherlands.  
Measurement of the source air kerma strength was carried out in-air using a 
jig, in a phantom and repeated in a Well chamber. The results were compared 
with the value of the source air kerma strength provided on the source 
certificate (see Chapter 3, section 3.1 for measurement procedure). The in-air 
method of calibration used a 0.6 cc PTW 31002 Farmer type chamber. 
Temperature and pressure corrections were done for every measurement and 
recorded. On the first day of carrying out measurements, the     was 
obtained from an average atmospheric pressure of 1014.8 kPa and 23.5 0C 
temperature: 
                   Average temperature = 23.5 0C 
                   Average Pressure     = 1014.8 kPa 
From                    
                                          (
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)                           . . . (4.1) 
                                                 (      
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)   
                                                = 1.011 
This temperature and pressure correction factor was used to correct all the 












4.2 Stability Check 
The dosimeter, i.e. the PTW Farmer chamber and electrometer combination 
may not be stable due to environmental or voltage and current fluctuations. A 
stability check is done to verify the stability of the dosimeter by checking it 
against a stable long half-life Strontium-90 source whose activity is known and 
documented. The first step that was done each day for verifying the stability of 
the measuring instrument was to obtain the temperature and pressure 
correction factor,    . A typical stability check calculation done on the 24th of 
January 2012 is shown below. The     was calculated as shown above in 
section 4.1:  
The PTW Farmer chamber (without cap) was put inside a Strontium-90 source 
to measure the activity of the strontium against the known decayed value of 
the strontium as shown in Figure 4.1. Three measurements of the source 
dose rate were done for one minute each (see Table 4.1 below). 
Table 4.1: Stability check measurements 
Readings R1 R2 R3 RAv Rcor 
[·10-2 Gy·min-1] 3.745 3.744 3.744 3.744 3.785 
 
where       is corrected for temperature and pressure i.e.  
                                                                                                  … (4.2) 
The reference dose rate, Rref of the Strontium-90 source for that particular day 
was retrieved from the electrometer and was found to be: 
                                                                       
The dosimeter stability was calculated using equation 4.3 below: 
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                 Dosimeter stability    (          
    
)                                   ... (4.3) 
                                                    (           
     
)         
                                                   =   0.45%  
Stability values that fall within 1 % confirm that the dosimeter is stable and 
values above this threshold may warrant further investigations to be done in 
order to rectify any problems and maintain equipment stability within the 1 % 
limit. 
Figure 4.1 shows a picture of the set-up to do a stability check. 
 



















           a is a army type barometer, 
b is the Strontium-90 check source with the PTW Farmer chamber 
inserted, 
c is a thermometer measuring the temperature of the environment 
inside the check source, 
            d is the electrometer and Farmer chamber cable . 
4.3 In-Air Calibration 
The 192Ir source strength was determined using a custom made in-air jig (see 
Figs 3.1(a), (b)and 3.3). In general, for each source strength measurement, 
the reference air kerma rate, Ḱ (cGy.h-1) was calculated from which the source 
strength, Sk’  (cGy/h m2) was then obtained. After setting up the in-air source 
calibration setup as shown in Figs 3.1 and 3.2, several exposures were done 
with the source on either side of the ion chamber. The duration of each 
exposure was 600s and the measurements obtained are shown below. Two 
sets of air kerma strength were calculated using the in-air method as follows: 
Table 4.2: Measurements obtained using the Air kerma strength 
calibration factor 
Readings R1 R2 R3 R4 RAv 
Charge (nC) 72.732 72.699 72.792 72.789 72.753 
 
The air kerma strength was calculated using equations 3.2, 3.3 and 3.5 in the 
previous chapter i.e. 
                                                            Ḱ     
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where,  
                                                                             , 
and the air kerma strength,  
                                                            Ḱ       
With all the symbols in the above equations representing the same properties 
and values given in section 3.1 of the previous chapter, and the temperature 
and pressure correction calculated as from equation 4.1 above.  
     
(                                                (    )  
      
 
                                 
Repeating the same experiment under the same conditions, the air kerma 
strength was obtained again using the absorbed dose to water calibration 
factor of the dosimeter. The results of the measurements are shown in Table 
4.3 below: 
Table 4.3: Measurements obtained using absorbed dose to water 
calibration factor  
Readings R1 R2 R3 R4 RAv 
Charge (nC) 65.459 65.445 65.481 65.483 65.467 
 
Using the same equations as used above, the following is the calculation for 
the source air kerma strength on that particular time and date: 
     
(                                                (    ) ) 
      
 













4.4 In-Phantom Calibration 
On the same day and time, the air kerma strength was obtained using a 
customized PTW 9193 acrylic phantom (Fig 3.5(a)). The calibration setup in 
Fig 3.5(b) was used to measure the exposure in terms of charge that was 
used to calculate the air kerma strength using the air kerma strength and 
absorbed dose calibration factors as shown in sections 4.4.1 and 4.4.2 below. 
4.4.1 Air Kerma Strength from Air Kerma Strength Measurements 
Results of measurements obtained using the air kerma calibration factor are 
shown in Table 4.4 below. 
Table 4.4: Measurements obtained using the air kerma strength 
calibration factor 
Readings R1 R2 R3 R4 RAv 
Charge (nC) 96.235 96.271 96.254 96.224 96.246 
 
Equation 3.6 from Chapter 3 was used to calculate the air kerma strength 
using the average exposure measurement above, i.e. 
                                 {             }                                                       
                                           
                                                       (  
  
)                                            
                                                     
 
4.4.2 Air Kerma Strength from Absorbed Dose to Water 
Measurements 
The air kerma strength was also calculated using measurements done in the 
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Table 4.5: Measurements obtained using absorbed dose to water 
calibration factor 
Readings R1 R2 R3 R4 RAv 
Charge (nC) 97.137 97.122 97.125 97.120 97.126 
 
From equation 3.7 from the previous chapter, the air kerma strength was 
calculated as follows: 
    {
 
     
 
(    ⁄ ) 
(    ⁄ ) 
               }                     
                                     
                                    (
  
  
)                                                     
                               
4.5 Well Chamber Calibration 
The local standard against which all local calibrations are checked is the Well 
chamber. After performing measurements at the maximum-source-strength-
position using the method described in section 3.1.2 of the previous chapter, 
four-radiation exposure readings were taken at the maximum source strength 
position. Each exposure lasted 600 seconds and the measurements obtained 
are shown below:  
Table 4.6: Measurements done in Well Chamber 
Readings R1 R2 R3 R4 RAv 














Equation 3.5 was then used to calculate the source strength, i.e. 
                                               
       
 
     
  
                                                 
                          
      
             
                                                                    
Where     =1, since the duration of the source transport time is negligible for 
measurement times equal to or greater than six hundred seconds. All the 
other symbols and values in the above relationship are the same as described 
in section 3.1.2 of chapter 3.  
4.6 Calibration of Semiconductor Probes 
After calculation of the source strength, the bladder and rectum diode probes 
were then calibrated in the custom made cylindrical PMMA calibration 
phantom, i.e. PTW T9193 phantom as described in section 3.4 of the previous 
chapter (see Fig 3.5 (b)). A software program (MultiSoft) was used to obtain 
calibration factors for the individual diodes. The MultiSoft software captured 
the individual calibration factors into the program and the program used these 
factors to measure the dose received by the diodes when exposed to 
radiation.  
For all dose measurements obtained using the PTW Farmer ionization 
chamber, the measurements were corrected for temperature and pressure 
changes. Calibration factors and corresponding dose measurements were 
carried out following the procedure described in the previous chapter, i.e. 
section 3.4. The calibration factors and corresponding dose measurements 
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Table 4.7: Calibration factors and corresponding dose measurements 
made in a PTW T9193 phantom 
Calibration factors (e + 005 Gy/C) 
0.6 cc Ion 
Chamber 
(cGy) 




B R1 R2 R3 R4 R5 Duncor Dcor B R3 R1 R2 R4 R5  
4.098 4.695 4.073 4.096 4.106 4.217 283.7 284.0 281.9 283.4 251.0 256.0 255.0 244.0 0.47 
4.077 4.661 4.055 4.077 4.094 4.202 283.5 283.8 283.5 284.1 248.7 272.9 278.2 248.6 0.10 
4.132 4.749 4.118 4.148 4.157 4.274 283.8 284.1 284.0 284.3 250.0 275.0 275.0 249.0 0.07 
  
See Appendix 2 for the output of the MultiSoft computation of calibration 
factors. The calibration factors collected over the period the study was being 
carried out are shown below in Table 4.8. From Table 4.8 it is clear to notice 
that the calibration factors change with time. The sensitivity and 
characteristics of the semiconductor materials change with time with 
prolonged exposure to radiation. The standard deviation of the gradual 
change of the calibration factors ranged from (0.211 x 105) up to (0.710 x 105),  
while  average monthly deviation also ranged from (0.061 x 105) up to (0.256 
x 105) over the nine month period over which the study was carried out. 
Dose measurements recorded by the 0.6 cc Farmer ionization chamber, 
bladder diode and rectum diode number 3 were comparable after the third trial 


















Table 4.8: Calibration factors obtained and used during the research  
Calibration factors (e + 005 Gy/C) 
Date Bladder R1 R2 R3 R4 R5 
24.10.11 3.966 4.366 4.169 4.270 4.035 4.023 
26.10.11 4.132 4.749 4.118 4.148 4.157 4.274 
26.10.11 4.098 4.695 4.073 4.096 4.106 4.217 
26.10.11 4.077 4.661 4.055 4.077 4.094 4.202 
04.11.11 4.013 4.650 4.349 4.521 4.386 4.459 
04.11.11 4.463 5.286 4.905 5.007 4.902 5.039 
14.11.11 4.463 5.286 4.905 5.007 4.902 5.039 
07.03.12 4.151 5.967 5.114 4.359 3.582 3.017 
16.04.12 3.988 6.670 5.499 4.760 3.851 3.226 
24.07.12 4.513 5.372 5.029 5.190 4.963 4.985 
 
After the correct calibration factors were obtained and loaded into the 
MultiSoft program, the dose measurements made in the T9193 phantom were 
accurate, precise and comparable at the reference positions, i.e. 0.6 cc 
Farmer chamber, bladder diode and rectal diode number 3. The doses 
registered after exposure to the same amount of dose were comparable to 
within 0.07 % as shown in Table 4.7. 
4.7 Pilot Study in Phantom 
After confirming the accuracy of the 0.6 cc PTW 31002 Farmer chamber, 
obtaining correct calibration factors and consequently calibrating the bladder 
and rectal diode probes, a pilot study was carried out in a Alderson- Rando 
phantom. The diode holes in the phantom were too small for the rectal diode 
probe to be inserted in the phantom; therefore, the pilot studies were only 
carried out using the bladder probe (see section 3.4.4 for detailed account of 
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were inserted into the phantom, anterior- posterior and lateral radiographs 
were taken and developed. Dose reference points, i.e. ICRU point A  (ICRU, 
1985) and the measuring volume of the bladder diode B1, were marked on the 
radiographs. The radiographs were scanned into a treatment planning 
software program called Flexiplan (see Appendices 3 and 4). 
A treatment plan was made to deliver a dose of 2 Gy (as shown in Figure 4.2 ) 
at the ICRU point A and the plan exported to the treatment computer and 
machine where it was delivered to the phantom and measured by the bladder 
diode. Several dose measurements were made in the phantom and the 
results are shown in Table 4.9 below and see also Appendix 5 for a dose 
measurement report from MultiSoft produced after the dose delivery. B1 is the 
expected bladder diode reading obtained from treatment planning (Figure  
4.2) and obtained after measuring in the Alderson-Rando phantom (Table 4.9)  
Table 4.9: Bladder Diode Dose Measurements in Alderson-Rando 
phantom 
Readings R1 R2 R3 Rav 
Bladder diode 
measurement, B1 (Gy) 
1.142 1.141 1.143 1.142 
 
 
Figure 4.2: Dose control point report for the treatment plan of 2 Gy at 












4.8 In-vivo and In-vitro Dosimetry 
Table 4.10 Ring and Tandem applicator dose results 
 
TPS Doses  Planned from X-rays [Gy] Measured Diode dose [Gy] 
ICRU Dose Reference Points Patient Diode Doses Patient Diode Doses Phantom Doses 
 
Study Applicator A Dose Bladder R1 R2 Rectum Bladder Bladder Rectum Bladder Rectum 
1 1 R2T7 7.0 6.20 4.05 4.55 2.06 5.63 5.400 2.145 4.378 2.588 
2 
  
6.0 5.74 4.11 4.72 3.04 4.58 4.675 3.404 4.094 3.024 
3 2 R2T5 6.5 
 





4 3 R2T7 7.5 4.66 6.40 5.20 2.20 3.04 3.350 2.486 2.690 2.900 










7 6 R2T7 9.0 7.75 5.97 5.84 2.81 7.15 7.162 3.994 5.512 2.810 
8 7 R2T7 9.0 9.11 6.28 6.07 3.09 4.74 4.027 4.576 4.499 3.694 





10 9 R2T5 7.0 4.10 4.49 3.52 1.71 3.04 3.060 2.631 2.718 2.519 
11 
  
7.0 3.96 4.58 4.33 1.94 5.25 3.458 2.737 4.601 2.258 
12 10 R2T7 7.0 5.50 3.83 4.77 2.38 3.34 2.852 3.820 2.737 3.095 
13 
  
6.0 4.66 3.39 4.35 1.97 3.71 3.114 3.025 3.321 2.586 
14 
  
6.5 7.18 3.52 4.37 2.43 3.87 3.157 4.390 3.532 3.025 
15 11 R2T5 6.0 3.45 3.60 3.90 2.00 3.36 2.930 3.000 2.869 2.509 
16 
  
6.0 5.32 3.15 3.82 1.87 3.04 2.735 3.128 2.470 2.075 
17 
  
6.0 4.45 2.92 4.32 2.11 3.95 3.434 3.664 3.576 2.707 
18 12 R2T5 6.5 6.55 4.50 4.30 1.65 5.84 4.487 2.443 4.297 1.995 
19 
  
5.5 7.42 3.16 3.28 1.80 4.01 3.558 2.897 4.028 2.79 










22 14 R2T5 7.0 6.73 5.13 4.91 
 
2.18 1.787 2.903 2.148 2.400 
23 
  
6.0 4.41 3.91 3.98 1.86 3.50 3.841 3.097 3.440 2.301 
24 15 R2T7 7.0 4.39 4.38 4.27 1.67 7.34 3.301 2.375 6.197 2.129 
25 
  
7.0 4.8 3.92 4.20 2.18 2.71 2.797 4.011 2.457 2.824 
26 16 R2T7 7.0 4.73 4.34 4.29 1.64 5.63 5.263 2.565 5.373 2.267 
27 
  
6.0 5.00 3.09 3.59 1.88 
 
1.963 3.326 1.690 2.934 
28 
  
6.0 3.79 3.74 3.9 2.45 1.92 1.841 3.722 
  
 
17 R2T5 7.0 4.21 4.62 4.84 2.45 4.34 5.808 3.549 3.946 3.000 
29 18 R2T5 7.0 4.44 3.89 3.58 1.73 5.03 4.482 2.787 8.531 2.377 
30 
  
7.0 3.39 4.23 4.44 2.15 4.20 4.025 3.074 4.097 2.928 
31 
  
7.0 2.43 4.68 5.5 3.57 2.15 
  
3.496 2.676 
32 19 R2T5 7.0 7.51 4.47 4.35 2.05 0.98 0.886 3.194 1.037 2.943 
33 
  
6.0 2.95 3.09 4.04 2.49 1.00 1.053 4.144 1.005 3.014 
34 
  
7.0 3.24 4.05 4.95 2.51 1.09 1.329 3.486 0.989 3.546 
35 20 R2T5 7.0 4.82 4.72 4.75 2.03 2.95 3.091 3.058 2.911 2.962 
36 
  
6.5 3.86 4.69 4.4 1.70 3.13 2.587 2.478 3.138 2.038 
37 
  
6.5 3.53 4.61 5.32 1.63 5.36 4.845 2.356 4.520 2.276 
38 21 R2T7 7.0 10.14 4.36 4.33 1.67 5.60 4.498 2.716 4.090 1.957 
39 
  
6.0 5.74 3.96 4.19 2.30 2.93 2.822 3.783 2.498 2.884 
40 
  
6.0 3.12 4.90 5.38 1.99 4.19 3.823 3.479 3.451 2.332 
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In-vivo dosimetry in patients was carried out following the procedure 
described in the previous chapter (section 3.5). 
 A total number of 30 patients participated in the study. The ring and rigid 
tandem applicator was used on twenty-two patients and forty-one insertions 
had sufficient data captured in the study (see Table 4.10 above). The vaginal 
cylinder-rigid tandem combination (combo) applicator was used on eight 
patients and data from 11 insertions was successfully recorded in the study as 
shown in Table 4.11 below.  
Table 4.11 Vaginal Cylinder – Tandem Applicator dose results 
   
TPS Doses Planned from X-rays [Gy] Measured Doses [Gy] 
   
ICRU Dose Reference Points TPS Diode Patient doses Phantom Doses 
 
Study Applicator A Dose Bladder R2 Surface Bladder Rectum Bladder Rectum Bladder Rectum 























4 8 3cmCyl6cmTan 5.00 3.67 4.92 
 
2.67 2.32 2.960 2.770 2.720 2.816 
5 10 3cmCyl6cmTan 5.00 3.57 5.54 
 
4.10 2.56 4.040 4.430 5.018 4.870 
6 
  
5.00 5.05 5.11 7.03 2.51 3.20 2.609 4.901 2.510 3.200 
7 14 3cmCyl4cmTan 5.00 4.63 5.49 9.50 2.85 2.66 2.694 3.533 2.683 3.561 
8 
  
5.00 8.43 4.36 5.93 9.50 2.14 12.17 3.192 
 
3.192 
9 17 3cmCyl6cmTan 5.00 1.82 5.04 7.70 2.96 2.59 2.682 3.866 3.095 3.558 
10 20 3cmCyl4cmTan 5.00 3.43 5.41 
 
2.60 
   
2.526 1.880 
11 21 3cmCyl4cmTan 6.00 4.62 9.27 
 
5.33 1.70 5.052 2.758 4.999 2.272 
 
The orientation of the treatment setup of the treatment applicators relative to 
the bladder and rectum diodes in each patient was reproduced in a water 
phantom as described in section 3.5.3 of the previous chapter. In-vitro dose 
measurements were done for each insertion that had been done in patients 












Table 4.12 TPS, in-vivo and in- vitro doses for Ring &Tandem applicator 
 
TPS Doses [Gy] Measured Doses [Gy] Ratios 
ICRU Dose Reference Points Patient Doses Patient Doses Phantom Doses ICRUB/ ICRURectum TPSBladde TPSRectum Bladderp Rectump 
No. study Aplctr  A Bladder R1 R2 Rectumd Bladderd Bladderp Rectumd Bladderw Rectumw TPSBladder TPSRectum BladderD DiodeD Bladderw Rectumw 
1 1 R2T7 7.0 6.20 4.05 4.55 2.06 5.63 5.400 2.450 5.630 2.060 1.148 1.857 1.043 0.841 1.000 1.000 
2 
  
6.0 5.74 4.11 4.72 3.04 4.58 4.675 3.404 4.580 3.040 1.228 1.387 0.980 0.893 1.000 1.000 
3 2 R2T5 6.5 
 











4 3 R2T7 7.5 4.66 6.40 5.20 2.20 3.04 3.350 2.486 2.521 2.900 1.391 2.092 0.907 0.885 1.206 0.759 
5 4 R2T5 6.0 
  




















7 9 R2T7 9.0 7.75 5.97 5.84 2.81 7.15 7.162 3.994 7.150 2.810 1.082 1.462 0.998 0.704 1.000 1.000 
8 11 R2T7 9.0 9.11 6.28 6.07 3.09 4.74 4.027 4.576 4.499 3.694 2.262 1.326 1.177 0.675 1.054 0.836 











10 13 R2T5 7.0 4.10 4.49 3.52 1.71 3.04 3.060 2.631 2.718 2.519 1.340 1.338 0.993 0.650 1.118 0.679 
11 
  
7.0 3.96 4.58 4.33 1.94 5.25 3.458 2.737 4.601 2.258 1.145 1.582 1.518 0.709 1.141 0.859 
12 15 R2T7 7.0 5.50 3.83 4.77 2.38 3.34 2.852 3.82 2.737 3.095 1.928 1.249 1.171 0.623 1.220 0.769 
13 
  





3.52 4.37 2.43 3.87 
 




0.554 1.096 0.803 
15 16 R2T5 6.0 3.45 3.60 3.90 2.00 3.36 2.930 3.000 2.869 2.509 1.177 1.300 1.147 0.667 1.171 0.797 
16 
  
6.0 5.32 3.15 3.822 1.87 3.04 2.735 3.128 2.47 2.075 1.945 1.222 1.112 0.598 1.231 0.901 
17 
  
6.0 4.45 2.92 4.32 2.11 3.95 3.434 3.664 3.576 2.707 1.296 1.179 1.150 0.576 1.105 0.779 





3.16 3.28 1.80 4.01 
 




0.621 0.996 0.645 





























6 4.41 3.91 3.98 1.86 3.50 3.841 3.097 3.440 2.301 1.148 1.285 0.911 0.601 1.017 0.808 
24 23 R2T7 7.0 4.39 4.38 4.27 1.67 7.34 3.301 2.375 6.197 2.129 1.330 1.798 2.224 0.703 1.184 0.784 
25 
  
7.0 4.80 3.92 4.20 2.18 2.71 2.797 4.011 2.457 2.824 1.716 1.047 0.969 0.544 1.103 0.772 
26 
  
7.0 4.44 4.63 4.59 1.91 1.45 1.930 2.215 
   
2.072 0.751 0.862 





3.09 3.59 1.88 
  







29 25 R2T5 6.0 3.79 3.74 3.90 2.45 
  









6.0 3.90 3.93 




     31 26 R2T5 7.0 4.44 3.89 3.58 1.73 5.03 4.482 2.787 8.531 2.377 0.991 1.285 1.122 0.621 0.590 0.728 
32 
  
7.0 3.39 4.23 4.44 2.15 4.20 4.025 3.074 4.097 2.928 0.842 1.444 1.043 0.699 1.025 0.734 
33 
          
3.496 2.676 
      34 27 R2T5 7.0 7.51 4.47 4.35 2.05 
  









6.0 2.95 3.09 4.04 2.49 
  









7.0 3.24 4.05 4.95 2.51 
  







37 28 R2T5 7.0 4.82 4.72 4.75 2.03 2.95 3.091 3.058 2.911 2.898 1.559 1.553 0.954 0.664 1.013 0.700 
38 
  
6.5 3.86 4.69 4.40 1.70 3.13 2.587 2.478 3.138 2.038 1.492 1.776 1.210 0.686 0.997 0.834 
39 
  
6.5 3.53 4.61 5.32 1.63 5.36 4.845 2.356 4.520 2.276 0.729 2.258 1.106 0.692 1.186 0.716 
40 29 R2T7 7.0 
 
4.36 4.33 1.67 5.60 
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Table 4.13 TPS, in-vivo and in-vitro doses for Vaginal Cylinder-Tandem 
applicator 
 
TPS Planned Doses [Gy] Measured Doses [Gy] Ratios 



















Study Applicator A  Bladder Rectum Bladderp  Rectump  Bladderw Rectumw Bladder Rectum 









































4 8 3Cyl6Tan 5 3.67 4.92 2.67 2.32 2.960 2.770 2.720 2.816 1.240 1.776 0.902 0.838 1.088 0.984 
5 10 3Cyl6Tan 5 3.57 5.54 4.10 2.56 4.040 4.430 5.018 4.870 0.884 1.251 1.015 0.578 0.805 0.910 
6 
  
5 5.05 5.11 2.51 3.20 2.609 4.901 2.510 3.200 1.936 1.043 0.962 0.653 1.039 1.531 
7 14 3Cyl4Tan 5 4.63 5.49 2.85 2.66 2.694 3.533 2.683 3.561 1.719 1.554 1.058 0.753 1.004 0.992 
8 
  
5 8.43 4.36 9.50 2.14 12.170 3.192 
 
3.192 0.693 1.366 0.781 0.670 
 
1.000 
9 17 3Cyl6Tan 5 1.82 5.04 2.96 2.59 2.682 3.866 3.095 3.558 0.679 1.304 1.104 0.670 0.867 1.087 
10 20 3Cyl4Tan 5 3.43 5.41 2.60 
   
2.526 1.880 




















CHAPTER 5 ANALYSIS OF RESULTS 
5.1 Basic Principles and Terminology of Measurements 
“A measurable quantity (briefly - measurand) is a property of phenomena, 
bodies, or substances that can be defined qualitatively and expressed 
quantitatively.” (Rabinovich, 2005). Measurable quantities are also known as 
physical quantities. Three important features describe a measurement 
(Rabinovich, 2005); 
1. A measurement is a numerical number that corresponds to a property 
of an object; 
2. Measuring instruments are used to perform a measurement; 
3. Measurement is at all times an experimental course of action; 
Measurement is the process that estimates a value of a quantity (NASA, 
2010). Measurements are always accompanied by errors.  Measurement 
uncertainty expresses the lack of knowledge and need to quantify the 
magnitude and sign of a measurement error. A measurement result must 
always include a statement of uncertainty in the estimate. 
5.1.1 Uncertainty Analysis 
Performing general uncertainty analysis usually follows the steps below: 
i. Defining the measurement process, 
ii. Identification of the sources of error, 
iii. Estimation of uncertainties, 
iv. Combining uncertainties,   
v. Reporting the analysis of the results. 
In any uncertainty analysis procedure, the measurand whose value is being 
estimated through measurement is identified. The test setup, environmental 
conditions, technical information about the instruments, reference standards 
and other instruments used and the procedure for performing the 
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is used to identify possible sources of error. When the sources of error are 
found, statistical properties of the measurement errors are derived from the 
distributions of the data and estimates of the uncertainties are obtained 
(NASA, 2010).   
Uncertainty describes the inaccuracy of a measurement result, while error 
describes the components of the uncertainty. A measurement error is 
defined as the variation of a measurement from the true value of the 
measurable quantity, expressed in absolute or relative form (Rabinovich, 
2005). Uncertainty expresses the magnitude of the measurement error in a 
measurement result (IAEA-TECDOC-1585, 2008), e.g. 
                                                                                                     … (5.1) 
Where, 
                              is the true value,  
                              is the measured value, and  
                             is the range and represents the measurement uncertainty. 
In the above relationship, the true value of the measurement,   is between 
       and         (IAEA-TECDOC-1585, 2008) 
5.1.2 Experimental Errors and Uncertainty 
Experimental error is the difference between a measurement and the true 
value. Accuracy and precision are used to measure experimental error. No 
physical quantity can be measured with perfect certainty; errors are always 
present in any measurement (Taylor, 1997). If a quantity is measured and 
then the measurement is repeated again, it is most likely that a different value 
will be measured the second time. This makes it difficult to obtain the “true” 
value of a physical quantity. However, if refined experimental methods are 
used and great care is exercised in making measurements, errors can be 
reduced. In common speech, the words accuracy and precision are often 
used interchangeably. However, scientifically there is distinction between the 













Accuracy refers to the relationship between a measured quantity and the real 
value of that quantity. The accuracy of a single measurement can be defined 
as the difference between the measured value and the true value of the 
quantity. The accuracy of a measurement is therefore limited by such things 
as the calibration and sensitivity of the instruments used, the ability to read the 
meters and mistakes made in recording the measurements (Bevington & 
Robinson, 1992). 
5.1.2.2 Precision 
Precision measures how close a measured value is to the true or accepted 
value. Precision also refers to the amount of scatter in a series of 
measurements of the same quantity. It is possible for a measurement to be 
very precise, but at the same time not very accurat . For example, if a voltage 
is measured using a digital voltmeter that is incorrectly calibrated, the answer 
will be precise (repeated measurements will give almost the same result to 
several decimal places) but the measurements will be  inaccurate (all of the 
measurements will be wrong). By making a series of  measurements of some 
quantity, we can obtain an estimate of the precision of each individual 
measurement (Bevington & Robinson, 1992).  
 
Not accurate                 Accurate                   Not accurate               Accurate                   
Not Precise                  Not precise                Precise                       Precise 
Figure 5.1: An illustration of accuracy and precision of measurements in 
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Error and uncertainty are also often used interchangeably. Nevertheless, it is 
important to be aware of the distinction between the actual error in a given 
measurement (i.e. in the amount by which the measured value differs from the 
true value) and the uncertainty in a measurement. In many experiments, the 
true value of the quantity being measured is not known, and therefore the 
actual error in the result is not definite. Usually both the systematic and 
random error of the error must be estimated. The systematic error is 
estimated priori while the random error is estimated posteriori (Rabinovich, 
2005).  
 
When   single measurements are repeated to account for random errors,       
values of the measured quantity will be obtained i.e.     , i = 1, . . . ,  . This 
can be written as (Rabinovich, 2005), 
                                                                                                   . . . (5.2) 
Where, 
                                                  is the actual value of the measured quantity,  
                                                   is the error in the measured quantity. 
 
The error   , has both the random and systematic components, i.e. 
                                                                                                     . . . (5.3) 
Where, 
                                                   is the random error, and  
                                                    is the systematic error. 
 
Repeating measurements collects information about the random error. 
Information about the systematic error is obtained from properties of the 
measuring instrument, the method of measurement and the conditions 
present during the measurement process. The systematic error cannot be 
directly obtained from the measurements.  
However, it is still possible to make an estimate of the uncertainty (or the 












properties of the measuring instruments. The precision of any individual 
measurement can be determined by calculating the standard deviation of the 
mean, also known as the standard uncertainty of the mean,   ̅ (Rabinovich, 
2005, p. 31): 
                                       ̅   √
∑ (     ̅)
  
   
 (   )
                                   … (5.4) 
Where  ̅ is the average value of   and where   is the number of 
measurements. The standard error can be taken as an estimate of the 
uncertainty or probable error since any individual measurement has a 
reasonable probability of being in error by at least that amount. However, the 
actual error in a measurement can be much larger than the standard deviation 
if there are systematic errors, e.g. errors in calibration of measuring 
instruments that affect measurements the same way. It is good practice to 
compare measured values of quantities with given or theoretical values and 
the estimate the percentage error (Taylor, 1997). 
Additional to the measured quantity  , a confidence interval that determines 
the confidence of the limits of the random error in the measurement results 
can be made, i.e. 
                                                ̃             ̃       , 
Where         ̅, and    represents the   percent point of the  - distribution 
and relies on the confidence probability   and the number of degrees of 
freedom,        –    (Rabinovich, 2005) 
5.2 Classification of Measurement Errors 
In performing measurements for calibration of measuring instruments, high 
levels of accuracy and precision are maintained to obtain the measurable 
quantity so that it can be used for this purpose instead of the true value of the 
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estimated using indirect data. In carrying out measurements, there are 
fundamental components that constitute any measuring system, i.e. 
 
- the method of measurement, 
- the measuring instrument; and  
- the person making the measurements. 
 
 Any imperfection inherent in each of the fundamental components of 
measurement contributes directly to the measurement error. This can be 
expressed as, in the general form, 
 
                                                                                                                 ... (5.3) 
Where, 
                                              is the measurement error,  
                                             is the methodological error,  
                                               is the instrumental error and  
                                              is the personal error. 
 
Several factors can give rise to each separate measurement error component 
stated above (IAEA-TECDOC-1585, 2008).   
5.2.1 Outlying Results  
Gross (outlying) errors are errors that considerably surpass the acceptable 
error margins for a given set of conditions in which the measurements are 
done (Rabinovich, 2005). The conditions under which the measurements are 
done may include the properties of the measuring instrument used, the 
method of measurement, the qualifications and expertise of the experimenter 
and the physical conditions, i.e. the temperature, humidity and pressure. For a 
given experiment, a sudden change in temperature may drastically affect 
measurements for an experiment that has to be carried out at constant 












multiple measurements and it is possible to remove the outliers from the data 
analysis.  
For a given ordered series,                       , from all   , the 
mean   and the standard deviation is calculated and then T is calculated 
using the following formula: 
                                               |    ̅ |
 
                                        ... (5.4) 
Where   is calculated using the formula for calculating the standard deviation 
above (equation (5.1)). The outcome of the calculation will either be,  
                                                       
|    ̅ |
 
                                   ... (5.5) 
or, 
                                                       
|    ̅ |
 
                                  ... (5.6) 
When experiments are done and measurements recorded, it is difficult to 
predict if    or    will be checked. Appendix 6 shows the 0.5, 1, and 5 
percentage points of    of the corresponding unilateral check of the series 
                      . A critical value    (taken from Appendix 6), for 
which the significance level is half of the level used for checking  the data was 
adopted (Rabinovich, 2005). For a calculated value of       in equations 5.5 
and 5.6 above, greater than   , a subsequent value of     or    was removed 
from the data that was considered in the analysis. This procedure was used to 
identify outliers from results of measured data as shown in the Appendices 7  
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Mean 6.762 5.279 4.237 4.489 3.880 3.514 3.567 2.177 3.202 2.690 
Std Dev 0.850 1.824 0.865 0.696 1.579 1.356 1.503 0.503 0.721 0.501 
Median 7.000 4.765 4.180 4.350 3.870 3.392 3.496 2.060 3.097 2.707 
Minimum 5.500 2.430 2.920 3.100 0.980 0.886 0.989 1.140 1.410 1.478 
Maximum 9.000 10.140 6.400 6.070 7.340 7.162 8.531 3.570 4.905 4.121 
 
Table 5.2: Statistics of Raw Data Ratios of doses obtained using Ring 


















Mean 1.825 1.129 1.095 1.015 1.456 0.679 0.805 1.191 
Std Dev 1.357 0.241 0.165 0.187 0.351 0.119 0.122 0.196 
Median 1.476 1.109 1.105 1.044 1.387 0.661 0.782 1.171 
Min 0.729 0.820 0.590 0.525 0.966 0.544 0.641 0.712 
Max 8.476 2.224 1.369 1.344 2.258 1.043 1.334 1.507 
 
 However, it can also be true that an abnormal observation may in fact be an 
indication of an unknown property of the subject under study (Rabinovich, 
2005). Below are reasons that may merit an experimenter to remove an outlier 
from measured data (Rabinovich, 2005): 
1. Real measurements generally are comprised of a small number of 
observations and the chances of obtaining more than two outliers in the 
results will be very small. Therefore, the outlier under concern may not 













2. An outlier is considerably different from the majority of the measured 
data and hence skews the average value of the data set, thereby 
increasing the inaccuracy of measurements.  
 
In this study the experimenter eliminated outliers using the unilateral check i.e. 
eliminating data entries above certain critical values of distribution ,           
    
   |    ̅ |
 
 or       
   | ̅     |
 
  (Rabinovich, 2005) (Appendices 6). A few 
in-vitro dose data entries for ring and tandem applicator dose were identified 
and eliminated as outliers using upper 5% significance level identification of 
outliers (Appendix 7). Almost half of all the dose data for the vaginal cylinder 
and tandem combination (combo) was identified as outliers using the same 
method as above (Appendix 8).  The outliers were not eliminated from the 
combo results and the data was processed as-it-was without any alterations. 
Removal of the ‘outliers’ would have further reduced the sample size. This 




Blunders arise from errors made by the experimenter. For instance, a slip of 
the pen while writing up results of observations or recording a measurement 
that is not corrected for temperature and pressure for experiments that are 
influenced by environmental conditions could result in a blunder. Non-
statistical methods are used to identify and remove blunders from measured 
data sets (IAEA-TECDOC-1585, 2008). In carrying out this research, it was 
observed that on certain occasions, the positions of placement of bladder and 
rectal diode probes used for planning were different compared to the final 
position of the diode probes after treatment. This was as a result of bladder 
and rectal diode probes slipping out from placement positions (where they 
would have been secured) inside the patient during treatment. On such 
incidents, the measured doses were different from the dose computed from 
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excluded in the data analysis. Tables 5.3 and 5.4 below show general 
statistics of processed data without outliers and blunders. 
 




















Mean 6.795 4.990 4.227 4.414 4.204 3.780 3.731 2.124 3.135 2.679 
Std Dev 0.864 1.610 0.886 0.670 1.407 1.156 1.682 0.472 0.719 0.522 
Median 7.000 4.450 4.120 4.340 3.950 3.446 3.532 2.040 3.058 2.676 
Minimum 5.500 2.950 2.920 3.100 1.450 1.930 0.989 1.140 1.410 1.478 
Maximum 9.000 9.110 6.400 6.070 7.340 7.162 8.531 3.260 4.905 4.121 
 
Ratios of TPS planned doses at ICRU reference points to in-vivo and in-vitro 
measured doses were also computed to further analyse the data (see 
Appendices 8 and 9). Tables 5.4 and 5.5  show  results for ratios of processed 
data obtained for the two applicators considered in this study. 
Table 5.4 Statistics of ratios for processed data without blunders and 



















1.368 1.127 1.082 0.980 1.475 0.689 0.773 1.182 
Std Dev 
0.418 0.278 0.134 0.183 0.358 0.115 0.160 0.177 
Median 
1.330 1.088 1.098 1.021 1.403 0.664 0.772 1.189 
Minimum 
0.729 0.751 0.590 0.525 0.966 0.544 0.641 0.712 
Maximum 
































1.152 0.982 0.988 0.969 1.825 0.761 0.788 1.053 
Std Dev 
0.501 0.111 0.085 0.109 0.701 0.155 0.136 0.197 
Median 
0.914 1.015 1.000 1.007 1.665 0.712 0.786 1.000 
Minimum 
0.679 0.781 0.817 0.805 1.043 0.578 0.526 0.815 
Maximum 
1.936 1.104 1.066 1.088 3.361 1.062 1.000 1.532 
Statistical values of raw and processed data for the ring and tandem 
applicator doses are almost the same. However, from Tables 5.2 and 5.4, 
comparison between raw and processed data ratios of planned ICRU to in-
vivo doses show that the outliers grossly skew the data, i.e. raw data ratio of 
ICRUBladder/BladderPtn = 1.825 and processed data ratio of ICRUBladder/BladderPtn 
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5.2.2.1 Frequencies and Descriptive Statistics of Processed Data 
Since most of the data obtained for the combo applicator was identified as 
outliers using the procedure in section 5.2.1, only data acquired from using 
the ring and tandem applicator was used for the further analyses.   
 
(a)                                         (b)                                           (c) 
Figure 5.2: Frequency distributions of (a) TPS planned, (b) In-vivo, and 
(c) In-vitro Bladder doses  
5.2.2.1.1 Skewness 
Skewness occurs when one tail of a frequency distribution is longer than the 
other, and when the mean and median are different, then the curve is said to 
be skewed (Rabinovich, 2005). Most common inferential statistical tests 
assume that the dependent variable is normally distributed. Therefore, it is 
imperative to have knowledge on how the data is skewed. A perfect normal 
distribution curve has a skewness of zero. 
Figure 5.2 shows the frequency distributions of the TPS planned together with 
in-vivo and in-vitro measured doses showing differing degrees of skewness. 
The skewness values range from 0.066 (for TPS bladder) to 0.872 (for TPS 
Rectum) as shown in Table 5.6 below.  
The shapes of the TPS planned and in-vivo bladder doses are almost similar 
in appearance although the values of the skewness are different, i.e. 0.066 
and 0.200 for the TPS and in-vivo bladder doses respectively. Similar analysis 
of the rectum doses show almost similar frequency distributions for the TPS 
planned and in-vivo doses although they also have different skewness values 












both the bladder and rectum, the shapes of frequency distributions of in-vitro 




When a frequency distribution has greater peaks than the normal curve, it has 
positive kurtosis and is said to be leptokurtic. If a data distribution is fairly flat 
with well pronounced tails, it will have negative kurtosis and is said to be 
platykurtic. Kurtosis does not greatly affect the results of most statistical 



















                                   
N 
Valid 31 37 31 37 33 38 
Missing 7 1 7 1 5 0 
Std. Deviation 1.628 0.527 1.332 0.721 1.682 0.515 
Variance 2.651 0.278 1.774 0.520 2.831 0.265 
Skewness 0.066 0.872 0.200 0.356 0.700 0.399 
Std. Error of Skewness 0.421 0.388 0.421 0.388 0.409 0.383 
Kurtosis -0.253 0.585 0.907 0.362 1.070 0.901 
Std. Error of Kurtosis 0.821 0.759 0.821 0.759 0.798 0.750 
Range 6.360 2.430 6.280 3.500 7.540 2.640 
Percentiles 
25 3.040 1.765 2.852 2.599 2.611 2.274 
50 3.870 2.050 3.434 3.058 3.532 2.692 
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analyses and therefore was not used in the analysis of the results in this 
study. 
5.2.3 Methodological Errors  
Methodological errors arise due to lack of sufficient knowledge on the theory 
of the phenomena on which the measurement is based on and using incorrect 
principles to obtain the estimate of the measurable quantity. In particular, the 
error caused by the threshold discrepancy between the model of a specific 
object and the object itself is also a methodological error (IAEA-TECDOC-
1585, 2008). In this study, ratios were calculated to determine the 
methodological error for doses at ICRU (ICRU, 1985) reference points, in 
patients and in a water phantom. This was done to investigate and to prove 
the validity of the method used to obtain doses received by the bladder and 
rectum during gynaecological HDR brachytherapy (see Appendices 8 and 9). 
Doses at reference points obtained through computerised treatment planning 
were compared with doses measured in patients and doses measured in a 
water phantom to confirm the validity of computerised treatment planning and 
in-vivo doses as shown in the tables of results (see Appendices 8 and 9) and 
Tables 5.4 and 5.5 above. The average ratio of ICRU rectal point to in-vivo 
rectum dose was 1.475 ± 0.358 (range: 0.966-2.258) while ICRU bladder 
point to in-vivo bladder dose was 1.368 ± 0.418 (range: 0.729 -2.262) for ring 
and tandem applicator. The ratios of ICRU point to in-vivo dose for the rectum 
and bladder when using the vaginal combo applicator were 1.825 ± 0.701 
(range: 1.043 - 3.361) and 1.152 ± 0.501 (range: 0.679 – 1.936) respectively.  
The TPS algorithm used to compute the dose is based on using water as 
tissue-equivalent material. Therefore, the relationship between TPS planned 
doses, in-vivo and in-vitro doses was expected to be very close to unity (one), 
since all the three dosimetry methods all computed or measured dose at the 
‘same’ point. The mean ratios of TPS to in-vivo dose for the bladder and 
rectum were 1.127 ± 0.278 (range: 0.751 – 2.224) and 0.689 ± 0.115 
respectively for ring and tandem applicator insertions. Average TPS to in-vivo 
dose ratios for the bladder and rectum were 1.016 ± 0.073 (range: 0.902 – 












combo applicator insertions.  Average ratios of TPS to in-vitro dose  were 
0.988 ± 0.085 (range: 0.817 – 1.066) and 0.788 ± 0.136 (range: 0.526 – 
1.000) for the bladder and rectum respectively for vaginal combo insertions. 
While mean ratios of TPS to in-vitro dose for the bladder and rectum were 
1.082 ± 0.134 (range: 0.590 – 1.359) and 0.773 ± 0.160 (range: 0.641 – 
1.000) respectively for ring and tandem applicator insertions. 
 
The average ratios for bladder doses were ‘reasonably’ close to unity i.e. TPS 
to in-vivo, TPS to in-vitro, in-vivo to in-vitro were 1.127, 1.082 and 0.98 
respectively as compared to the average ratios for rectum doses, i.e. TPS to 
in-vivo, TPS to in-vitro, in-vivo to in-vitro were 0.689, 0.773 and 1.181 
respectively. The ratios for the bladder doses confirm the methodological 
validity of the methods used in the study. However, there were large error 
margins observed in results obtained from computations and measurements 
in the rectum had which suggests the unfitness of the data to be used for 
useful in-vivo – TPS dose comparisons. The in-vitro measurements were 
useful in confirming the relationship patterns between TPS and in-vivo doses. 
 
5.2.4 Personal Errors 
 
These errors arise due to the mere fact that humans perform the 
measurements. “A measure of the non-reproducibility of a measurement 
permitted by the experimenter is the limits of measurement error or 
uncertainty estimated by the experimenter.” (IAEA-TECDOC-1585, 2008). 
Measurement errors can also be classified based on their properties. In this 
respect, systematic and random errors are distinguished.  
5.2.5 Systematic Errors 
“A measurement error is said to be systematic if it remains constant or 
changes in a regular fashion in repeated measurements of one and the same 
quantity” (IAEA-TECDOC-1585, 2008). Corrections can be employed to 
remove errors from measurements. However, it is very difficult to remove all 
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fraction of error that will be present in measurements and this becomes the 
systematic component of the measurement error. Systematic errors are 
obtained experimentally either: 
 by evaluating a measurement  against another measurement of the 
same quantity obtained using a different method, or 
  by using a measuring instrument  that is more accurate.  
However, systematic errors are usually obtained by theoretical analysis (see 
Table 5.3) of the measurement conditions, relying on information on known 
properties of the measurable quantity and of measuring instruments. 
5.2.5.1 Instrumental Errors 
Instrumental errors are caused by using faulty measuring instruments in 
making measurements. The normal/intrinsic error of instruments, i.e. the error 
obtained under reference conditions is usually differentiated from additional 
errors that may arise because of variations in the values of influence 
quantities from reference conditions (IAEA-TECDOC-1585, 2008). For 
modern instruments, advances in the reading and regulating mechanisms of 
measuring instruments have greatly reduced personal errors such that they 
are normally insignificant. The equipment that was used during this study is 
regularly calibrated and monitored through frequent consistency quality 
control checks. Corrective measures are applied as and when necessary to 
keep the instrument up to specifications and reasonable error margins.   
 
From chapter 4, section 4.1, the average value of the dosimeter stability over 
the duration of the study was found to be ± 0.52%. The uncertainty in the 
calibration/stability of the dosimeter contributes directly to the uncertainty in 
the measurements and therefore is included in determining the overall error in 















                                                                                           . . . (5.4) 
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where: 
   
  
       
 is the uncertainty in the stability of the dosimeter and the average 
value of this uncertainty is  0.52 % in this study. 
 Therefore, in the above equation, the factor    = 1.0052, 
                  is the unprocessed in-vivo or in-vitro measured dose, 
         is the processed true dose at a given point which incorporates 
the errors. 
Measurements done to confirm the reference dosimetric quantity, i.e. the air 
kerma strength, were done using the in-air, in-phantom methods and in a Well 
chamber. This was done to obtain the uncertainty in the calibration of the 
diode probes. An analysis of values of air kerma strength obtained using the 
three different methods is shown in Table 5.7 below. From Table 5.7, all the 
methods used to calculate the air kerma strength produced values close to the 
Well Chamber measurement (see Appendix 9), i.e. the values were on 
average within 2 % of the local standard. Since this study was concerned with 
determining the dose received by organs at risk during gynaecological HDR 
brachytherapy, air kerma strength was calculated based on the absorbed 
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]        
Well Chamber (WC) 21.592 0.000 
In Air (IA)           i Exposure 21.790 - 0.917 
                        ii Absorbed Dose 21.595 - 0.014 
In Phantom (IP)  i Exposure 21.804 - 0.982 
                        ii Absorbed Dose 21.809 -1.010 
 
where, 
   is exposure or absorbed dose based air kerma values obtained 
using the in-air or in-phantom method. 
 A comparison between measurements obtained using the well chamber and 
the decay adjusted manufacturers value (on the certificate) was done using 
MS Excel spreadsheet and was found to be -2.2% (see Appendices 1 and 
13). 
5.2.5.2 Static and Dynamic Errors 
Measurement errors can also be grouped into static and dynamic errors. All of 
the errors described in the previous sections above are static errors.  
 “Dynamic errors are caused by the inertial properties of measuring 
instruments.” (IAEA-TECDOC-1585, 2008).  
“The inertial properties of an instrument can be such, however, that the 
changes in the measurable quantity over the measurement time will give rise 













The resultant data set of instantaneous values gathered from the experiments 
will not be concurrent with the change of the measurand in time because of 
the dynamic error.  
Table 5.8: Change in the diode calibration factors with time (dynamic 
error) 
Calibration Factors 
(e + 005 Gy/C) 
Date B R1 R2 R3 R4 R5 
24.10.11 3.966 4.366 4.169 4.270 4.035 4.023 
26.10.11 4.132 4.749 4.118 4.148 4.157 4.274 
26.10.11 4.098 4.695 4.073 4.096 4.106 4.217 
26.10.11 4.077 4.661 4.055 4.077 4.094 4.202 
04.11.11 4.013 4.650 4.349 4.521 4.386 4.459 
04.11.11 4.463 5.286 4.905 5.007 4.902 5.039 
14.11.11 4.463 5.286 4.905 5.007 4.902 5.039 
07.03.12 4.151 5.967 5.114 4.359 3.582 3.017 
16.04.12 3.988 6.670 5.499 4.760 3.851 3.226 
24.07.12 4.513 5.372 5.029 5.190 4.963 4.985 
       
Minimum 3.966 4.366 4.055 4.077 3.582 3.017 
Maximum 4.513 6.670 5.499 5.190 4.963 5.039 
Mean 4.186 5.170 4.622 4.544 4.298 4.248 
Range 0.547 2.304 1.444 1.113 1.381 2.022 
Standard deviation 0.211 0.710 0.526 0.419 0.478 0.703 
Monthly deviation 0.061 0.256 0.160 0.124 0.153 0.225 
Weekly deviation 0.015 0.064 0.040 0.031 0.038 0.056 
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The instantaneous dynamic error occurs because of variation in the rate of 
change of a measurable quantity and inertial properties of an instrument with 
respect to a separate instantaneous quantity being measured at a given time. 
If a varying quantity is measured using a measuring instrument, the difference 
between a measurement obtained and the actual process of variation of the 
recorded quantity in time gives the dynamic error of the given dynamic 
measurement. (IAEA-TECDOC-1585, 2008). In this research, the 
instantaneous dynamic error arose from calibrating the diode probes at given 
time intervals. This was necessitated by the fact that the response of the 
diode semiconductor material (used to make the diode) changes with time 
because of exposure to radiation (Huyskens, et al., 2001). The rate at which 
periodical calibrations of the diode probes were made, influenced the 
magnitude of the dynamic error that is present in the measurements. Table 
5.8 above shows an MS Excel spreadsheet output for computing the variation 
of the calibration factors of the in-vivo diodes with time. The calibration factors 
vary weekly from at least 0.36% to 1.32% due to the change in the measuring 
properties of the diodes. 
For independent sources of error, the combined error is calculated as by 
equation 5.5 below (NASA, 2010), 
                                    √  
    
     
                                   . . . (5.5) 
Therefore, combining the instrumental errors above to get the expected 
Systematic error gives, 
                                     √(                         )  
                                      
5.2.6 Random Error 
“If there are differences between the results of separate measurements, and 
these differences cannot be predicted individually and any regularities 












scatter of the results is called the random error” (IAEA-TECDOC-1585, 
2008).  
Table 5.9: Random error (intra-patient) for TPS, in-vivo and in-vitro 







TPS (Gy) In-Vivo (Gy) In-vitro (Gy) INTRA Patient Dose Variation (Gy) 
Rectum Bladder Bladder Rectum Bladder Rectum BTPS Bd Bw RTPS Rd Rw 
13 7 1.71 3.04 3.060 2.631 2.718 2.519 2.21 0.398 1.883 0.23 0.106 0.261 
 
7 1.94 5.25 3.458 2.737 4.601 2.258 
      
16 6 2.00 3.36 2.930 3.000 2.869 2.509 0.32 0.195 0.399 0.13 0.128 0.434 
 
6 1.87 3.04 2.735 3.128 2.470 2.075 0.59 0.504 0.707 0.11 0.664 0.198 
 
6 2.11 3.95 3.434 3.664 3.576 2.707 0.91 0.699 1.106 0.24 0.536 0.632 
23 7 1.67 7.34 3.301 2.375 6.197 2.129 4.63 0.504 3.740 0.51 1.636 0.695 
 











25 6 2.45 
  
3.722 3.946 3.000 







        
26 7 1.73 5.03 4.482 2.787 8.531 2.377 0.83 0.457 4.434 0.42 0.287 0.551 
 
7 2.15 4.20 4.025 3.074 4.097 2.928 
      
27 7 2.05 
  
3.194 1.037 2.943 
  




3.486 0.989 3.546 
      
28 6.5 1.7 3.13 2.587 2.478 3.138 2.038 2.23 2.258 1.382 0.07 0.122 0.238 
 
6.5 1.63 5.36 4.845 2.356 4.520 2.276 
      
              
       
Mean 1.595 0.806 1.712 0.268 0.520 0.452 
       
St Dev 1.316 0.641 1.583 0.151 0.549 0.197 
       
Max 4.630 2.258 4.434 0.510 1.636 0.695 
       
Min 0.320 0.195 0.048 0.070 0.106 0.198 
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Performing measurements of the same quantity repeatedly makes it possible 
for random errors to be identified in a measurement system.  From section 
5.1, the random error   with probability equal to the confidence probability   
has limits      (Rabinovich, 2005): 
                                                           ̅ 
 In this study, the treatment planning and in-vivo dosimetry measurement 
procedures for each fraction were done only once on each patient for each 
treatment fraction. It was only the in-vitro measurements that could be 
repeated (at most) three times in order to establish the random error (see 
Appendices 10 and 11) 
 
“The quality of measurements that reflects the closeness of the results of 
measurements of the same quantity performed und r the same conditions is 
called the repeatability of measurements” (IAEA-TECDOC-1585, 2008).  
 
Random errors are small when there is good repeatability of measurements. 
Data processing to obtain the intra-patient random error per critical organ was 
done and the results are shown in Table 5.9 above.  Data for patients who 
had unchanged prescription dose for at least two insertions was selected for 
this type of analysis. Data from seven patients fitted this criterion and was 
used in the intra-patient dose variation investigation. The differences between 
individual doses recorded per each insertion per critical organ per patient 
were calculated and tabulated as shown in Table 5.9. The standard deviation 
of the variation of intra-patient dose for the entire population sample was 
regarded as the random error. This random error was the expected dose 
difference between insertions. 
 
The same analysis could not be done for the vaginal combo applicator since 
only data from three patients matched the selection criterion and the sample 
was too small for a valid analysis to be done on the data. A separate analysis 












patient-to-patient, i.e. inter-patient dose variation. The same data sample from 
the previous analysis was used for this investigation. In order to calculate the 
inter-patient dose variation per critical organ, the mean intra-patient variation 
for the entire sample (from the previous analysis) was subtracted from each 
individual dose value recorded for each critical organ and the results obtained 
are shown in Table 5.10 below. 
 
Table 5.10: Random error (inter-patient) for TPS, in-vivo and in-vivo 








TPS (Gy) In-Vivo (Gy) In-vitro (Gy) INTER-Patient Dose Variation (Gy) 
Rectum Bladder Bladder Rectum Bladder Rectum BTPS Bd Bw RTPS Rd Rw 
13 7 1.71 3.04 3.060 2.631 2.718 2.519 0.62 0.408 0.171 0.04 0.414 0.191 
 
7 1.94 5.25 3.458 2.737 4.601 2.258 
      
16 6 2.00 3.36 2.930 3.000 2.869 2.509 4.31 2.063 4.035 0.38 1.508 0.261 
 
6 1.87 3.04 2.735 3.128 2.47 2.075 0.27 0.309 0.659 0.04 0.558 
 
 
6 2.11 3.95 3.434 3.664 3.576 2.707 0.91 0.699 1.106 0.24 0.536 0.632 
23 7 1.67 7.34 3.301 2.375 6.197 2.129 4.63 0.504 3.740 0.51 1.636 0.695 
 











25 6 2.45 
  
3.722 3.946 3.000 







        
26 7 1.73 5.03 4.482 2.787 8.531 2.377 0.83 0.457 4.434 0.42 0.287 0.551 
 
7 2.15 4.20 4.025 3.074 4.097 2.928 
      
27 7 2.05 
  
3.194 1.037 2.943 
  




3.486 0.989 3.546 
      
28 6.5 1.70 3.13 2.587 2.478 3.138 2.038 2.23 2.258 1.382 0.07 0.122 0.238 
 
6.5 1.63 5.36 4.845 2.356 4.520 2.276 
      
       
Mean 1.825 0.993 1.947 0.267 0.664 0.453 
       
Std Dev 1.598 0.735 1.821 0.175 0.586 0.214 
       
Max 4.630 2.258 4.434 0.510 1.636 0.695 
       
Min 0.270 0.309 0.048 0.038 0.122 0.191 
 
The standard deviation of this process was regarded as the expected inter-
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brachytherapy treatment three times for a full treatment course, only one in-
vivo dosimetry procedure was possible per insertion. During the following 
insertions/treatments, it is difficult to reproduce the ICRU dose reference 
points and diode probes positions and there is little that can be done about 
this except to perform the procedure in such a way that it will be as painless, 
comfortable and technically adequate as required by the treatment protocols. 
Therefore, only the in-vitro dose measurements could be repeated at least 
twice as shown in Appendices 10 and 11. Table 5.10 and 5.11 below show a 
summary of the data processing results obtained using MicroSoft Excel 
spreadsheet for in-vitro measurements. The mean standard deviation for the 
bladder and rectum, i.e. BladderStd and RectumStd were regarded as the 
random error. This random error is the intra-measurement expected error, i.e. 
the personal error or reproducibility of the in-vitro measurements.  
Table 5.11: Determining Random Error from repeated in-vitro 







Mean 0.150 0.111 
Std Dev 0.150 0.135 
Median 0.075 0.059 
Min 0.002 0.000 














Table 5.12: Determining random error from repeated in-vitro 








Mean 0.083 0.299 
Std Dev 0.094 0.441 
Median 0.030 0.107 
Min 0.008 0.018 
Max 0.211 0.966 
 
In performing in-vitro measurements using the ring and tandem applicator, the 
resultant dose variation due to random errors was ± 0.150 Gy and ± 0.135 Gy 
for the bladder and rectum respectively. Dose variations observed after using 
the combo applicator were ± 0.094 Gy and ± 0.441 Gy respectively. From the 
results, it is clear that a greater random error was obtained in carrying out in-
vitro measurements for the combo applicator rectum dose. One of the 
contributing factors may be the fact that since the radiation sources are close 
to the surrounding tissue when using the combo applicator, the dose to the 
rectum wall and the dose gradient within the surrounding tissue will be very 
high. Therefore, a slight displacement in the reference dose point position 
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5.3 Combining Uncertainties 
The methodological error was not included in the final error expressions in this 
study. However, measures were taken to periodically monitor and correct for 
these errors in order to prevent these errors from affecting the dose 
computations and measurements. Instrumental and personal errors were 
used to estimate the uncertainty in the in-vivo and in-vitro measured doses. 
 
From equation 5.3,  
                                E = Em + Ei + Ep                     
The combined error in measuring the in-vitro doses can be expressed as 
follows: 
5.3.1 Ring and Tandem 
(a) Expected error in bladder dose measurements 
     (         )   (        )   
where   is the true value of the quantity as given in equation 5.1. 
 
 
(b) Expected error in rectum dose measurements 
   (         )   (        )   
5.3.2 Combo Applicator  
(a) Expected error in bladder dose measurements 
     (         )   (        )   
 
 
(b) Expected error in rectum dose measurements 













5.4 Correlations between TPS Planned, In-vivo and In-vitro Diode 
Doses 
This type of test was done to establish the strength of the linear relationship 
between two sets of data that was under comparison. A correlation coefficient 
was computed to indicate how the variability of the data obtained in the study 
was affected by the association between the two sets of data concerned. 
SPSS software was used to compute correlation coefficients for the paired 
samples shown in the output table below.  
This is the sample coefficient of determination   . The coefficient of 
determination has the following interpretation: 
{
                             
                        
                   
}   
∑(    ̂) 
∑(   ̅) 
 
                                               
                                                        
∑(    ̅)  (   ̅)(   ̅)   ∑(    ̅) 
∑(    ̅) 
                  
                                                          
   
 
      
               
 
and so, 
                  = 1 – the proportion of unexplained variability in the population, 
                    = the proportion of variability in y which is explained by the linear  
                       relationship, 
 
A large   , i.e.     close to 1, means that most of the variability is explained by 
the relationship, and having knowledge of the numerical value of the   
variable is more or less as efficient as knowledge of y. If    is close to zero, 
then there is a poor relationship between the two variables   and  .  There are 










   
 105 
explaining the relationship between variables. The     statistic is used also in 
regression analysis to determine whether a regression equation will be useful 
for predicting one variable using data from another. (Dowdy, et al., 2004) 
 
 
Table 5.13: SPSS output table for correlations of paired TPS planned, in-
vivo and in-vitro doses for the bladder and rectum 
 
 N Correlation Sig. 
Pair 1 TPS Bd & Bd 30 0.860 0.000 
Pair 2 TPS Bd & Bw 31 0.877 0.000 
Pair 3 Bd & Bw 30 0.828 0.000 
Pair 4 TPS Rd & Rd 36 0.757 0.000 
Pair 5 TPS Rd & Rw 37 0.745 0.000 
Pair 6 Rd & Rw 37 0.682 0.000 
 
From Table 5.13, all the paired samples had significant correlations, i.e. 
         for all the pairs.  Correlation coefficients for the bladder doses were 
more pronounced, i.e. all greater than 0.82 as compared to rectum doses with 
highest correlation coefficient 0.757. The highest correlation was between 
TPS planned and in-vitro measured dose for the bladder, which confirms the 













5.5 Differences in Means of TPS planned, In-vivo and In-vitro 
Doses 
The paired samples test or T- test was carried out to compare the means of 
two sets of data at any given time. The null hypothesis for this test was: 
                                H0:  d = 0 and Ha:  d   0 
Where  d was the population mean for the difference of the dose computed by 
the TPS, measured in-vivo and in-vitro. The tests were carried out using 
SPSS for a 95% confidence interval or p = 0.05 significance level and Table 
5.14 below gives a summary of the output results. 
Table 5.14: SPSS Output results for paired sample T-test of TPS 
planned, in-vivo and in-vitro doses for the bladder and rectum 
 









Interval of the 
Difference 
Lower Upper 
Pair 1 TPS Bd - Bd 0.470 0.827 0.151 0.161 0.779 3.110 29 0.004 
Pair 2 TPS Bd - Bw 0.160 0.827 0.149 -0.144 0.463 1.075 30 0.291 
Pair 3 Bd - Bw -0.260 0.971 0.177 -0.622 0.103 -1.466 29 0.153 
Pair 4 TPS Rd - Rd -1.029 0.482 0.080 -1.192 -0.865 -12.780 35 0.000 
Pair 5 TPS Rd - Rw -0.518 0.374 0.062 -0.643 -0.394 -8.427 36 0.000 
Pair 6 Rd - Rw 0.472 0.529 0.087 0.296 0.648 5.433 36 0.000 
From Table 5.14, the null hypothesis could not be rejected, i.e. the means of 
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bladder in-vitro dose data. This also means that the TPS computes valid in-
vivo doses for the bladder and rectum. 
Where, 
Bd is the in-vivo bladder diode dose measured,                                             
TPS Bd is the bladder diode dose calculated by the treatment planning system 
Bw is the in-vitro bladder diode dose measured 
Rd is the in-vivo rectum diode dose measured, 
TPS Rd is the rectum diode dose calculated by the treatment planning system, 
 Rw is the in-vitro rectum diode dose measured. 
5.6 Regression Analysis 
It was difficult to formulate a relationship between the TPS planned and the in-
vivo measured doses. Therefore, regression analysis was done using MS 
Excel software to attempt to describe the relationships. The MS Excel 
Regression analysis tool performs linear regression analysis by using the 
"least squares" method to fit a line through a set of observations. Regression 
makes it possible to analyze how a single dependent variable is affected by 
the values of one or more independent variables and then the results are used 
to predict future values using results from the regression process.  
Regression analyses of in-vivo against ICRU point doses for both the bladder 
and rectum was done and produced identical R-squared values of 0.096. 
These values were too low for any conclusion to be drawn from them. Table 
5.15 above gives a regression summary output for the comparison between 















Table 5.15: Summary output for regression of bladder in-vivo dose 
against ICRU bladder dose 
 
SUMMARY OUTPUT 
       
         Regression Statistics 
       Multiple R 0.774 
       R Square 0.599 
       Adjusted R 
Square 0.581 
       Standard Error 0.756 
       Observations 24 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 18.749 18.749 32.831 9.19E-06 
   Residual 22 12.563 0.571 
     Total 23 31.312       
   
         
  Coefficients 
Standard 







Intercept 1.149 0.492 2.336 0.029 0.129 2.170 0.129 2.170 
X Variable 1 0.624 0.109 5.730 9.19E-06 0.398 0.850 0.398 0.850 
From the output, the R-squared value of 0.5988 is not sufficient (ideally it 
should be close to unity, i.e. 1). Therefore, the regression model was not good 
enough to accurately predict the patients’ in-vivo doses from TPS doses as 
further proved by graph 5.1 below. From graph 5.1, the relationship between 
the series and predicted data is not good enough to give good predictions of 
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Figure 5.3: Regression line plot of the series and predicted data of 
bladder in-vivo versus ICRU reference point doses 
 
Even without any regression being done on the data, the spread or scatter 
does not clearly show a linear relationship.  
Another regression analysis was done using patient rectum in-vivo and rectum 
ICRU reference point doses. The output of this analysis is shown below in 
Table 5.16. A graph of the regression of the patient diode against TPS doses 
data was plotted together with the predicted dose data as shown in graph 5.2.  
From the output table, the R-squared value of 0.5685 is not good enough and 
strongly indicates the unreliability of the data for prediction purposes. Graph 
5.2 plotted to show the relationship between in-vivo and TPS planned doses 
reveals that there was no relationship between the two sets of data. The R-
squared values suggest the failure of regression analysis to fully explain the 
relationship between the rectum in-vivo and TPS doses. Therefore, as was 
recommended by previous investigators in HDR brachytherapy (Wäldhausl, et 
al., 2005) and (Hassouna, et al., 2011), all clinical decisions must based on 




















Regression Analysis of Bladder      














Table 5.16: Regression output for rectum in-vivo doses and ICRU 
reference point doses 
 
Regression Statistics 
       Multiple R 0.754 
       R Square 0.569 
       Adjusted R 
Square 0.556 
       Standard 
Error 0.491 
       Observations 37 
       
         ANOVA 
        
  df SS MS F 
Significance 
F 
   Regression 1 11.097 11.097 46.116 7.13E-08 
   Residual 35 8.422 0.241 
     Total 36 19.518       
   
         
  Coefficients 
Standard 







Intercept 0.636 0.376 1.690 0.100 -0.128 1.400 -0.128 1.400 
X Variable 1 1.176 0.173 6.791 7.13E-08 0.824 1.527 0.824 1.527 
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Figure 5.4 Regression line plot of the series and predicted data of 


























Regression Analysis of Rectum                   














CHAPTER 6 DISCUSSION AND CONCLUSION 
6.1 Summary 
From Chapter 1, the main aim of this research was to establish a 
complimentary and reliable method of performing in-vivo dosimetry during 
gynaecological high-dose rate (HDR) afterloading brachytherapy at Groote 
Schuur Hospital. This was necessitated by the need to verify the ‘in-vivo’ 
doses computed by the TPS using orthogonal radiographs. The study was 
also carried out to justify recommendations in literature that advise that in-vivo 
dosimetry should be done on patients using rectal and bladder dosimeters, 
additional to the computed dose calculations made by the TPS (Wäldhausl, et 
al., 2005).  
Commissioning and acceptance of the in-vivo diodes was a rigorous process 
that was carried out based on manufacturer instructions and guidelines, as 
well as by using recommendations made by previous investigators (Wilkinson, 
2010). Calibrating the source strength in the Well chamber, in the PTW T9193 
phantom and using the in-air method produced results that varied by a 
maximum of 1.01 %. The average combined systematic error during the study 
was found to be 2.8 %. The in-vivo diode probes were calibrated based on 
measurement of source strength. Verification of the calibration process in a 
Rando phantom produced accurate and precise results that confirmed the 
computerised TPS planned doses. In order to preserve accurate and precise 
measuring properties of the in-vivo diode dosimetry system, regular 
calibrations of the system had to be done, i.e. at least once every fortnight 
(Wäldhausl, et al., 2005). The weekly percentage deviation in the calibration 
factors ranged from 0.36 % to 1.32 %. Calibrating the in-vivo dosimetry 
system once every two weeks is likely to keep the dynamic error under 
control. The PTW 3D MP3 tank made a good phantom in which valid 
measurements were done. A water filled tank provided an equivalent patient 
scatter volume in which in-vivo measurements were replicated as shown in 
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To a large extent the in-phantom measurements successfully replicated real 
clinical situations under which patients were treated as reflected by the pattern 
of the relationships between TPS, in-vivo and in-vitro comparisons.  
Initially, inserting diode probes into patients took an additional seven to ten 
minutes. However, as more insertions were done and practical experience 
was gained, the additional time reduced roughly to an average time of four to 
five minutes.  The radiation oncologists were able to clearly distinguish and 
mark the ICRU dose reference points together with the bladder and rectum 
diode positions in the patients on most of the radiographs.  From the data 
analysis, ratios of ICRU to in-vivo doses were 1.4 ± 0.4 and 1.5 ± 0.4 for the 
bladder and rectum respectively for the ring and tandem applicator. For the 
combo applicator the corresponding ratios were 1.2 ± 0.5 and 1.8 ± 0.7 for the 
bladder and rectum. The results are very similar to results that were obtained 
by (Hassouna, et al., 2011), i.e. 1.2 ± 0.5 and 1.7 ± 0.5 for the bladder and 
rectum respectively using the ring and tandem applicator. The ratios confirm 
that the ICRU reference point dose system overestimates the dose that is 
measured in the OARs during HDR brachytherapy, similar to (Datta, et al., 
2006). However, when comparing the TPS planned to in-vivo doses, ratios 
obtained using the ring and tandem applicator were 1.1 ± 0.3 and 0.7 ± 0.1 for 
the bladder and rectum respectively. Ratios obtained using the combo 
applicator were correspondingly 1.0 ± 0.1 and 0.8 ± 0.2 for the bladder and 
rectum. The in-vivo bladder doses closely confirmed the TPS planned doses. 
However, for the rectum, the in-vivo doses were higher than the TPS 
calculated doses similar to what was also observed by (Kim & Pareek, 2003). 
Ideally all the ratios should be equal to one.  
Ratios of the TPS calculated to in-vitro dose measurements for the ring and 
tandem applicators were correspondingly 1.1 ± 0.1 and 0.8 ± 0.2 for the 
bladder and rectum, while for the vaginal combo applicator were 1.0 ± 0.1 and 
0.8 ± 0.1 for the bladder and rectum respectively. From Tables 5.4, 5.5 and 
6.1, it is evident that for the rectum, ratios of TPS planned to in-vivo doses are 












phenomenon is further confirmed by the ratios of the TPS planned to in-vitro 
doses. 
Table 6.1: Comparison of ratios of computed and measured doses 


















R & T 1.4 ± 0.4 1.1 ± 0.3 1.1 ± 0.1 1.0 ± 0.2 1.5 ± 0.4 0.7 ± 0.1 0.8 ± 0.2 1.2 ± 0.2 
Combo 1.2 ± 0.5 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.8 ± 0.5 0.8 ± 0.2 0.8 ± 0.1 1.1 ± 0.2 
 
The TPS underestimates the dose received by the rectum by roughly 20 %. 
This difference may be attributed to the inability to make corrections for 
inhomogeneities when using orthogonal radiographs for treatment planning 
purposes. This shortfall may be overcome by using computerised tomography 
(CT) based images for planning purposes (Datta, et al., 2006). However, in-
vivo doses for the bladder closely confirm the TPS calculated doses since 
ratios for all comparisons regarding the bladder except ICRU comparisons are 
close to unity.  
Since ICBT brachytherapy consists of several treatments on different days, 
data analysis was done to obtain the expected dose variation within the OARs 
in a patient (intra-patient) on different insertions during the course of 
treatment. This dose variation was regarded as being the intra-patient random 
error. The highest intra-patient random errors were obtained while measuring 
in-vivo bladder doses, i.e. TPS, in-vivo and in-vitro random errors were ±1.3 
Gy, ±0.6 Gy and ±1.6 Gy respectively for the ring and tandem applicator as 
shown in table 6.2 below.  
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 Intra-patient random errors (Gy) 








Ring  & 
Tandem 
±1.3 ±0.6 ±1.6 ±0.3 ±0.5 ±0.2 
This may be due to the proximity of the bladder to the ‘ring’ and the radiation 
sources. A slight displacement in the position of the in-vivo diode or ICRU 
reference point results in a marked dose change due to the high dose 
gradients close to the radiation source. The rectum intra-patient random errors 
were lower using both applicators with the highest dose being ±0.6 Gy for 
both applicators. The random error is smaller for the rectum since it is further 
away from the radiation source and changes in the displacement of diode or 
ICRU dose reference point positions do not produce large dose variations as 
compared to closer to the applicator and radiation sources. 
There were differences in doses that were observed for patients administered 
with the same treatment parameters, i.e. dose and applicator. This variation in 
dose from patient to patient (inter-patient) variation was regarded as the inter-
patient random error. The average inter-patient errors obtained using the ring 
and tandem applicator are shown in Table 6.3.  Maximum expected random 
error was observed for the bladder and lower random error observed in the 
rectum for the same reasons given above. 
For the in-vitro measurements, the average intra-measurement random error 
was obtained as ±0.2 Gy and ±0.1 Gy for the bladder and rectum respectively 
using the ring and tandem applicator while for the combo the random error 
was correspondingly ±0.1 Gy and ±0.4 Gy for bladder and rectum. See 
(Tables 5.10 and 5.11). 
 












 Intra-patient random errors (Gy) 
 Bladder Rectum 
Applicator TPS In-vivo In-vitro TPS in-vivo in-vitro 
Ring & 
Tandem 
±1.6 ±0.7 ±1.8 ±0.2 ±0.6 ±0.2 
 
Data analysis was done to compare the relationship between TPS, in-vivo and 
in-vitro doses and all the correlations were significant, i.e. p = 0.00. A paired 
T-test (p < 0.05) was done using SPSS to compare the means of TPS, in-vivo 
and in-vitro doses; the means were the same except for comparisons that 
included bladder in-vitro doses. The bladder diode’s proximity to the radiation 
sources probably magnified personal errors during in-vitro measurements and 
in the process distorted the data. This resulted in the T-test detecting different 
sample means for the bladder TPS – in-vitro and in-vivo - in-vitro dose inter-
comparisons.  
Regression analysis was done to compare TPS and in-vivo dose data. The 
regression analysis was done to confirm the following (Tyrell, 2009): 
- whether variables were related or not, 
- provide information about the relationship between the data, 
- describe (quantify) the strength of the relationship, and  
- ascertain whether it was possible to predict one variable from the other. 
The correlation coefficients showed that the TPS and in-vivo data are closely 
related, i.e. correlation coefficient for TPS-in-vivo was 0.86 for the bladder and 
0.75 for the rectum. Non-linear relationships with poor  -squared values were 
obtained after regression analysis of in-vivo against TPS dose data, i.e. 0.60 
and 0.57 for the bladder and rectum doses respectively. The relationship 
between the TPS and in-vivo doses observed in the study confirmed what was 
also observed by (Hassouna, et al., 2011) for both the bladder and rectum. 
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(Samiei, et al., 2006), regression analysis may not be used to effectively 
predict in-vivo doses from TPS doses.  
 
6.2 Uncertainties and Limitations  
 
Only the bladder diode could be verified in the Rando phantom because the 
diode holes in the phantom were too small for the rectum diode probe to fit in. 
However, since the bladder diode position and dose are analogous to the 
position and dose of the central diode of the rectum probe (diode number 3) in 
the PTW T9193 phantom, a confirmation of the bladder dose in Rando would 
have been confirmed by the central rectum diode if it were to be put in the 
same position to measure dose under the same conditions. Dose 
measurements done in the PTW T9193 confirmed the similarity of the bladder 
diode and central rectum diode measured doses. This reasoning and exercise 
was regarded as sufficient to substantiate the use of the rectum diode probe 
without verification in Rando or any other additional phantom. 
There was an intention to use ultrasound imaging (US) techniques to position 
applicators and diode probes in patients for treatment planning purposes 
(Barillot, et al., 1994); however, due to logistical problems and patients’ unmet 
demand for diagnostic US procedures, it was not possible to carry out US 
investigations in the study.  
 
The use of computerised tomography (CT) patient images was also not 
possible in this study. Since the CT scanner at the institution was a 
considerable distance away from the HDR brachytherapy treatment theatre, 
the radiation oncologist responsible raised concerns about possible 
movement of applicators during transfer of patients between the treatment 
couch and CT bed and moving to and from the CT scanner. The situation was 
made worse by the unavailability of scanning slots for HDR brachytherapy 
patients since it was a radiology dedicated CT. 
 
Positioning of the diodes in the water was critical for reproducing the 












more critical for the bladder since for most setups, the bladder was nearer to 
the source. Small displacements in diode positioning resulted in large dose 
deviations due to the steep dose gradient close to the radiation source. 
Although patients have varying anatomies, a standard tissue equivalent 
volume was used in the study. This may have introduced uncertainties in the 
in-vitro dose measurements. 
 
Occasionally it was difficult to identify the bladder diode on lateral radiographs 
after insertion. Large patient anatomies and double exposures made in 
acquiring images resulted in poor lateral radiographs, from which neither the 
Foley balloon nor bladder diode could be identified. Inserting a bladder probe 
through a urethra that already has a contrast balloon inserted is not easy. 
Often, the in-vivo bladder diode and could not be inserted because of this 
challenge. 
 
In certain events where dose measurements were done without clear 
identification of the organ at risk or in-vivo diode, the data was disregarded in 
the data analysis. In carrying out this research, every now and then the 
bladder and rectal diodes probes slipped out from positions where they should 
have been secured inside the patient. This was also experienced in previous 
studies (Hassouna, et al., 2011). On such occasions, the measured doses 
were different from the doses computed from the x-ray radiographs. These 
values were regarded as blunders and were excluded in the data analysis.  
 
6.3 Merits of the in-vivo dosimetry system 
 
In-vivo dosimetry is practiced in a relatively small number of institutions 
worldwide (Essers & Mijnheer, 1999). The low practice of in-vivo dosimetry 
around the world may be attributed to the perception that “the gain in patient 
treatment accuracy as a result of in-vivo dosimetry will be small compared to 
the additional workload and costs involved” (Essers & Mijnheer, 1999). A lot of 
research has been done to justify in-vivo dosimetry in gynaecological HDR 
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dosimetry in gynaecological HDR brachytherapy is critical and goes a long 
way to improve the quality assurance and outcomes of treatment. 
Calibrating the in-vivo dosimetry equipment once every fortnight helps to 
manage the dynamic error of the dose measuring instruments. The TPS and 
in-vivo dosimetry data for the bladder had a high correlation coefficient that 
confirmed the validity of both the TPS and in-vivo doses as true reflections of 
the actual dose received by the bladder. For the rectum, in-vivo dose 
measurements were higher when compared to TPS doses.  
 
(Yaparlvi, et al., 2008) findings suggest a strong relationship between the 
ICRU rectal reference dose with volumetric rectal doses. This information is 
useful in determining tolerance levels for the rectum during HDR 
brachytherapy treatment for gynaecological conditions. Recommendations 
from (Pӧtter, et al., 2006) suggest that using 3D image based clinical target 
volumes will most likely increase the therapeutic ratio, including target 
coverage and sparing of OARs.   
 
In-vivo dosimetry is a useful means of evaluating actual dose received by 
patients and avoid misadministration during HDR brachytherapy. Knowledge 
of the dose received by OARs during one treatment fraction enables radiation 
oncologists to adjust the prescription dose and treatment parameters for the 
subsequent treatments. In-vivo dosimetry allows verification measurements of 
the dose delivered to be done, thereby making a confidence check of the 
treatment (Alecu & Alecu, 1999). This study confirms previous in-vivo 
dosimetry studies made by (Wäldhausl, et al., 2005), that in-vivo diode 
accuracy and reproducibility is good enough for clinical use. In other words, 
computerised treatment planning and in-vivo dosimetry are separate 
complementary procedures that may be done simultaneously and separately 
to monitor dose received by OARs during HDR brachytherapy (Wäldhausl, et 
al., 2005). However,(Hassouna, et al., 2011) suggested that 3D image based 
dose calculations were a more accurate and reliable means of evaluating 












(Hassouna, et al., 2011) recommended therefore that clinical decisions must 
be based on 3D image based dose calculations. 
In South Africa, The Hazardous Substances Act, 1973 (Act 15 of 1973) and 
Regulations (No R1332 of 3 August 1973) governs the safe use of medical x-
ray equipment in the country. This Act has a provision that guides in-vivo 
dosimetry during external beam radiotherapy. In the current Act, there is no 
provision guiding in-vivo dosimetry in brachytherapy. In order to enhance 
medical practices that safeguard patients’ health and exploit the benefits of  
in-vivo dosimetry (Podgorsak, 2005), the Radiation Control Directorate, 
Department of Health ,South Africa may want to consider formulating  in-vivo 
dosimetry guidelines to be practiced during brachytherapy.  
6.4 Future Work 
During this study it was observed that there are many errors associated with 
patients’ movement during the treatment procedure. There is need to evaluate 
current methods and devices used to immobilize patients during 
gynaecological HDR brachytherapy. Ideal immobilizing techniques and 
devices should be able to immobilize patients from the waist-down and 
simultaneously hoist and secure the thighs and legs during HDR 
brachytherapy. Such devices must be fixed to the operating couch/table and 
ensure that the patient is comfortable, allowing no or only limited movement. 
This may assist in reducing patient movement during treatments, since it is 
very difficult for a person to remain motionless for long periods of times. Very 
often patients have to endure treatment durations of more than ten minutes, 
especially when the Iridium-192 source is no longer as active as right after a 
source change. Immobilisation may enable repeat insertions to be quicker, 
more reproducible and make patients more ‘comfortable’ during insertions. An 
additional graduated accessory (to be attached to the main immobilizing 
device) to secure source applicators and possibly the in-vivo diode probes in 
position may also be necessary.  
Future studies may also be done to investigate change in applicator positions 
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different bunkers. Transferring patients between the treatment and CT 
scanner bunkers is done at some centres that do not have gynaecological-
HDR-brachytherapy-dedicated CT scanners, but want to exploit the 
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APPENDIX 2: Calibration factors computed from MultiSoft Software  
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APPENDIX 3: Anterior- Posterior x-ray Plan of Alderson-Rando phantom  

















APPENDIX 4: Lateral x-ray Plan for Alderson-Rando phantom from  
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APPENDIX 5: Bladder diode dose measurement in Alderson-Rando  




















APPENDIX 6:  
Table.1 Critical values of the distribution of     
   |    ̅ |
 
 or       
   | ̅     |
 
 









3 1.155 1.155 1.153 
4 1.496 1.492 1.463 
5 1.764 1.749 1.672 
6 1.973 1.944 1.822 
7 2.139 2.097 1.938 
8 2.274 2.221 2.032 
9 2.387 2.323 2.110 
10 2.482 2.410 2.176 
11 2.564 2.485 2.234 
12 2.636 2.550 2.285 
13 2.699 2.607 2.331 
14 2.755 2.659 2.371 
15 2.806 2.705 2.409 
16 2.852 2.747 2.443 
17 2.894 2.785 2.475 
18 2.932 2.821 2.504 
19 2.968 2.854 2.532 
20 3.001 2.884 2.557 
21 3.031 2.912 2.580 
22 3.060 2.939 2.603 
23 3.087 2.963 2.624 
24 3.112 2.987 2.644 
25 3.135 3.009 2.663 
26 3.157 3.029 2.681 
27 3.178 3.049 2.698 
28 3.199 3.068 2.714 
29 3.218 3.085 2.730 
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APPENDIX 7:   Table 2 Upper 5% significance level Identification of Outliers, 
 -2.745 <     
   |    ̅ |
 
 < 2.745  ,  from Ring and Tandem applicator results 
 
Study Applicator Bladdericru R1icru R2icru Rectumtps Bladdertps Bladderd Rectumd Bladderw Rectumw 
1 R2T7 0.505 -0.217 0.087 -0.232 1.108 1.391 -1.466 0.540 -0.204 
  
0.253 -0.147 0.331 1.716 0.443 0.857 0.281 0.351 0.666 
2 R2T5 
 
-0.124 -0.387 0.146 -2.458 -2.592 -1.147 -2.373 -0.366 
3 R2T7 -0.339 2.501 1.021 0.047 -0.532 -0.121 -0.993 -0.583 0.418 
4 R2T5 0.182 -1.130 -1.995 -2.060 -2.458 -2.592 -2.486 -2.373 -2.419 
5 R2T5 2.057 2.143 2.098 1.755 -2.458 0.403 -0.370 -2.373 2.855 
6 R2T7 1.355 2.004 1.940 1.259 2.071 2.691 1.099 1.294 0.239 
7 R2T7 2.101 2.362 2.270 1.815 0.545 0.379 1.907 0.620 2.003 
8 R2T5 0.593 0.685 0.360 2.153 -2.458 -2.592 2.363 -2.373 1.233 
9 R2T5 -0.646 0.292 -1.392 -0.927 -0.532 -0.335 -0.792 -0.565 -0.342 
  
-0.723 0.396 -0.229 -0.470 0.868 -0.041 -0.645 0.688 -0.863 
10 R2T7 0.121 -0.471 0.403 0.404 -0.342 -0.488 0.858 -0.552 0.808 
  
-0.339 -0.980 -0.200 -0.411 -0.108 -0.295 -0.245 -0.164 -0.208 
  
1.043 -0.830 -0.171 0.504 -0.007 -0.263 1.649 -0.023 0.668 
11 R2T5 -1.003 -0.737 -0.846 -0.351 -0.330 -0.431 -0.280 -0.464 -0.362 
  
0.023 -1.258 -0.958 -0.609 -0.532 -0.575 -0.102 -0.730 -1.228 
  
-0.454 -1.524 -0.243 -0.132 0.044 -0.059 0.641 0.006 0.033 
12 R2T5 0.697 0.304 -0.272 -1.046 1.241 0.718 -1.053 0.486 -1.388 
  
1.174 -1.246 -1.737 -0.748 0.082 0.033 -0.423 0.307 0.199 
13 R2T5 -0.888 -0.888 0.303 -0.271 0.728 1.096 0.553 0.624 -0.244 
   
-1.477 -1.004 0.126 -2.458 -2.592 0.364 -2.373 0.590 
14 R2T5 0.796 1.032 0.604 
 
-1.077 -1.274 -0.415 -0.944 -0.579 
  
-0.476 -0.379 -0.731 -0.629 -0.241 0.241 -0.145 -0.084 -0.777 
15 R2T7 -0.487 0.165 -0.315 -1.007 2.192 -0.157 -1.147 1.750 -1.120 
  
-0.263 -0.367 -0.415 0.007 -0.741 -0.529 1.123 -0.738 0.267 
16 R2T7 -0.301 0.119 -0.286 -1.066 1.108 1.290 -0.884 1.202 -0.845 
  
-0.153 -1.327 -1.291 -0.589 -2.458 -1.144 0.172 -1.249 0.486 
  
-0.816 -0.575 -0.846 0.543 -1.242 -1.234 0.722 -2.373 -5.369 
17 R2T5 -0.586 0.443 0.504 0.543 0.291 1.692 0.482 0.252 0.618 
18 R2T5 -0.460 -0.402 -1.306 -0.887 0.728 0.714 -0.576 3.303 -0.625 
  
-1.036 -0.009 -0.071 -0.053 0.203 0.377 -0.177 0.353 0.474 
19 R2T5 1.224 0.269 -0.200 -0.252 -1.837 -1.939 -0.011 -1.683 0.504 
  
-1.277 -1.327 -0.645 0.623 -1.825 -1.815 1.307 -1.704 0.646 
  
-1.118 -0.217 0.662 0.663 -1.768 -1.612 0.394 -1.715 1.708 
20 R2T5 -0.252 0.558 0.374 -0.291 -0.589 -0.312 -0.199 -0.436 0.542 
  
-0.778 0.523 -0.128 -0.947 -0.475 -0.684 -1.004 -0.285 -1.302 
  
-0.959 0.431 1.193 -1.086 0.937 0.982 -1.174 0.634 -0.827 
21 R2T7 2.666 0.142 -0.229 -1.007 1.089 0.726 -0.674 0.348 -1.464 
  
0.253 -0.321 -0.430 0.245 -0.602 -0.510 0.807 -0.711 0.387 
  
-1.184 0.766 1.279 -0.371 0.196 0.228 0.385 -0.077 -0.715 














APPENDIX 8: Table 3 Upper 5% significance level Identification of Outliers,   -  
2.234 <     
   |    ̅ |
 
 < 2.234 ,  from cylinder and tandem (combo) applicator 
results 
   
 
                                                                                             







Study Applicator Bladdericru R2icru Surface Bladdertps Rectumtps Bladderd Rectumd Bladderw Rectumw 
1 5 3cmCyl4cmTan -0.336 0.267 -4.246 -4.246 -2.545 -4.246 -2.434 -4.246 -2.434 
2 6 3cmCyl6cmTan 0.310 -0.262 -4.246 -4.246 -2.706 -4.246 -2.392 -4.246 -2.392 
3 
  
0.742 -0.622 -4.246 -4.246 -2.277 -4.246 -2.392 -4.246 -1.970 
4 8 3cmCyl6cmTan -0.528 -0.476 -4.246 -2.200 -2.468 -1.978 -2.124 -2.162 -2.088 
5 10 3cmCyl6cmTan -0.588 -0.001 -4.246 -1.105 -2.284 -1.151 -0.852 -0.401 -0.515 
6 
  
0.298 -0.331 1.140 -2.323 -1.794 -2.247 -0.491 -2.323 -1.794 
7 14 3cmCyl4cmTan 0.047 -0.040 3.032 -2.062 -2.208 -2.182 -1.539 -2.190 -1.518 
8 
  
2.323 -0.905 0.297 3.032 -2.606 5.078 -1.800 -4.246 -1.800 
9 17 3cmCyl6cmTan -1.636 -0.384 1.653 -1.978 -2.261 -2.191 -1.284 -1.875 -1.520 
10 20 3cmCyl4cmTan -0.672 -0.101 -4.246 -2.254 -4.246 -4.246 -4.246 -2.310 -2.805 
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APPENDIX 9: Calibration checks for Well chamber (MS Excel 
Spreadsheet) 
DIVISION OF MEDICAL PHYSICS 
  
Ir-192 HDR Afterloader Source Change:  Calibration and checks for Well-chamber    
         
Date of measurement: 15/08/2011  11:15      
         
Dose meter    
  Temp. Pressure T&P Fact  
PTW4     20.0 °C 1013.3 hPa 1.0000  
         
Ionization Chamber Serial number  Polarizing voltage  
Well-type chamber 
0348  Note:      +300 V  
Type No. 077.091   
         
Apparent Activity Calibration Factor  
(From chamber calibration 
certificate) 
8.548 GBq/nA      
Dose Rate measured in nA 38.280 nA      
         
   Source Activity Date   
 Measured Activity 8.8437 Ci 15/08/2011  11:15  
 
Apparent Activity (in 
GBq) (Given by 
manufacturer) 
418.8600 GBq 22/07/2011  11:01  
 
Apparent Activity (in Ci) 
(Given by manufacturer) 11.3205 Ci `  





of source (B) 
[Manufacturer] 
% Correlation (<2% and >-
2%): 100*(A-B)/B 
15/08/2011  11:15 8.8437 Ci 9.0411 Ci -2.2% 
  
0 days      24.010  days    
         
Comments:    







Filed Certificate and 
Documents 
Filled     
Log Book  
           
      
  
       
Calculated  By 
  
Medical Physicist  














APPENDIX 10: Ring and Tandem In-vitro Bladder and Rectum Dose  
                          Measurements 
 
Ring & Tandem In-vivo doses [Gy] In-Vitro Measurements [Gy] 
 
Study Applicator Bladder Rectum R1 R2 R3 R4 Rav Rstd B1 B2 B3 B4 Bav Bstd 
1 1 R2T7 5.400 2.450 2.060 2.066 2.061 2.063 2.063 0.003 4.378 4.344 4.325 4.326 4.343 0.025 
2 
  
4.675 3.404 3.024 




   
4.094 
 
3 2 R2T5 
 
2.375 2.516 2.509 2.497 
 
2.507 0.010 
      
4 3 R2T7 3.350 2.486 2.635 2.637 2.637 3.299 2.802 0.331 2.782 2.785 2.786 2.575 2.732 0.105 
5 4 R2T5 
 
1.410 1.479 1.441 1.513 
 
1.478 0.036 
      
6 5 R2T5 4.060 2.935 4.151 4.090 
  
4.121 0.043 
      
7 6 R2T7 7.162 3.994 2.374 3.279 2.621 
 
2.758 0.468 5.166 5.987 5.391 
 
5.515 0.424 
8 7 R2T7 4.027 4.576 3.806 3.581 
  
3.694 0.159 4.451 4.546 
  
4.499 0.067 
9 8 R2T5 
 
4.905 3.295 3.336 3.293 
 
3.308 0.024 
      
10 9 R2T5 3.060 2.631 2.448 2.590 
  





3.458 2.737 2.252 2.273 2.249 
 
2.258 0.013 4.253 4.872 4.678 
 
4.601 0.317 
12 10 R2T7 2.852 3.820 3.139 3.050 
  





3.114 3.025 2.505 2.666 
  




   
4.390 3.004 3.046 
  
3.025 0.030 3.414 3.649 
  
3.532 0.166 
15 11 R2T5 2.930 3.000 2.467 2.551 
  





2.735 3.128 2.065 2.085 
  





3.434 3.664 2.684 2.730 
  
2.707 0.033 3.548 3.603 
  
3.576 0.039 
18 12 R2T5 4.487 2.443 1.947 2.042 
  




   
2.897 2.594 2.986 
  
2.790 0.277 3.818 4.238 
  
4.028 0.297 
20 13 R2T5 5.000 3.600 2.467 2.515 2.421 
 




   
3.464 2.986 2.986 
  
2.986 0.000 
      
22 14 R2T5 
 
2.903 2.251 2.548 
  





3.841 3.097 2.295 2.307 
  
2.301 0.008 3.487 3.401 
  
3.444 0.061 
24 15 R2T7 3.301 2.375 2.115 2.130 2.129 
 





2.797 4.011 2.810 2.837 
  
2.824 0.019 2.443 2.470 
  
2.457 0.019 
26 16 R2T7 1.930 2.215 2.282 2.201 2.317 
 






            
28 
   
3.326 2.975 2.893 
  






3.722 2.980 2.952 3.067 
 
3.000 0.060 4.011 3.894 3.946 
 
3.950 0.059 
29 18 R2T5 2.385 3.440 2.373 2.295 2.463 
 





4.482 2.787 2.836 3.020 
  





4.025 3.074 2.817 2.535 
  
2.676 0.199 3.547 3.445 
  
3.496 0.072 








   
3.194 3.029 3.005 
  




   
4.144 3.546 




   
0.969 
 
35 20 R2T5 
 
3.486 3.355 2.634 2.898 
 





3.091 3.058 2.096 1.985 
  





2.587 2.478 2.276 




   
4.520 
 
38 21 R2T7 4.845 2.356 2.253 1.660 
  




   
2.716 3.204 2.564 
  




    
2.645 2.713 2.690 
 
2.683 0.035 3.288 3.582 3.068 
 
3.313 0.258 
41 22 R2T3 
  
2.972 
   
2.972 
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APPENDIX 11: Vaginal Cylinder and Tandem in-vitro Bladder and 
Rectum Dose Measurements 
 
Vaginal Cylinder and 
Tandem 
 
TPS Doses [Gy] 









Bladder Rectum B1 B2 Bav Bst R1 R2 R3 Rav Rst 








    
2.512 2.510 2.505 2.509 0.004 
2 6 3Cyl6Tan 5.0  2.01 
 
2.420 






5.0  2.57 
 
2.420 
    
2.967 2.969 2.974 2.970 0.004 
4 8 3Cyl6Tan 5.0 2.67 2.32 2.960 2.770 2.722 2.711 2.717 0.008 2.869 2.762 
 
2.816 0.076 





5.0 2.51 3.20 2.609 4.901 2.300 2.304 2.302 0.003 4.055 4.183 
 
4.119 0.091 





5.0 9.50 2.14 12.17 3.192 




9 17 3Cyl6Tan 5.0 2.96 2.59 2.682 3.866 3.117 3.073 3.095 0.031 3.528 3.598 3.549 3.558 0.036 
10 20 3Cyl4Tan 5.0 2.60  
  
2.555 2.497 2.526 0.041 2.476 2.370 
 
2.423 0.075 
11 21 3Cyl4Tan 6.0 5.33 1.70 5.052 2.758 4.981 5.017 4.999 0.025 2.231 2.313 
 
2.272 0.058 
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